gene_symbol_DLV,gene_symbol_original,gene_name,aeid,aenm,signal_direction,analysis_direction,assay_component_endpoint_desc,gene_direction
AR,AR,androgen receptor,1855,ACEA_AR_agonist_80hr,gain,positive,"Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
AR,AR,androgen receptor,1856,ACEA_AR_antagonist_80hr,NA,NA,"Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Inhibition
ESR1,ESR1,estrogen receptor 1,2,ACEA_ER_80hr,gain,positive,"Data from the assay component ACEA_ER_80hr was analyzed into 2 assay endpoints. 
This assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
TP53,TP53,tumor protein p53,19,APR_HepG2_p53Act_1h_dn,loss,negative,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
TP53,TP53,tumor protein p53,20,APR_HepG2_p53Act_1h_up,gain,positive,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
TP53,TP53,tumor protein p53,39,APR_HepG2_p53Act_24h_dn,loss,negative,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
TP53,TP53,tumor protein p53,40,APR_HepG2_p53Act_24h_up,gain,positive,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
TP53,TP53,tumor protein p53,59,APR_HepG2_p53Act_72h_dn,loss,negative,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
TP53,TP53,tumor protein p53,60,APR_HepG2_p53Act_72h_up,gain,positive,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
AHR,AHR,aryl hydrocarbon receptor,1400,ATG_Ahr_CIS_dn,loss,negative,ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
AHR,AHR,aryl hydrocarbon receptor,63,ATG_Ahr_CIS_up,gain,positive,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-loop-helix protein"".",Activation
FOS,FOS,FBJ murine osteosarcoma viral oncogene homolog,1401,ATG_AP_1_CIS_dn,loss,negative,ATG_AP_1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
JUN,JUN,jun proto-oncogene,1401,ATG_AP_1_CIS_dn,loss,negative,ATG_AP_1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
FOS,FOS,FBJ murine osteosarcoma viral oncogene homolog,64,ATG_AP_1_CIS_up,gain,positive,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
JUN,JUN,jun proto-oncogene,64,ATG_AP_1_CIS_up,gain,positive,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
TFAP2A,TFAP2A,transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha),1402,ATG_AP_2_CIS_dn,loss,negative,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TFAP2B,TFAP2B,transcription factor AP-2 beta (activating enhancer binding protein 2 beta),1402,ATG_AP_2_CIS_dn,loss,negative,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TFAP2D,TFAP2D,transcription factor AP-2 delta (activating enhancer binding protein 2 delta),1402,ATG_AP_2_CIS_dn,loss,negative,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TFAP2A,TFAP2A,transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha),65,ATG_AP_2_CIS_up,gain,positive,"Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-turn-helix leucine zipper"".",Activation
TFAP2B,TFAP2B,transcription factor AP-2 beta (activating enhancer binding protein 2 beta),65,ATG_AP_2_CIS_up,gain,positive,"Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-turn-helix leucine zipper"".",Activation
TFAP2D,TFAP2D,transcription factor AP-2 delta (activating enhancer binding protein 2 delta),65,ATG_AP_2_CIS_up,gain,positive,"Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-turn-helix leucine zipper"".",Activation
AR,AR,androgen receptor,1403,ATG_AR_TRANS_dn,loss,negative,ATG_AR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
AR,AR,androgen receptor,115,ATG_AR_TRANS_up,gain,positive,"Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
SMAD1,SMAD1,SMAD family member 1,1404,ATG_BRE_CIS_dn,loss,negative,ATG_BRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
SMAD1,SMAD1,SMAD family member 1,66,ATG_BRE_CIS_up,gain,positive,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""Smad protein"".",Activation
CEBPB,CEBPB,"CCAAT/enhancer binding protein (C/EBP), beta",1410,ATG_C_EBP_CIS_dn,loss,negative,ATG_C_EBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
CEBPB,CEBPB,"CCAAT/enhancer binding protein (C/EBP), beta",67,ATG_C_EBP_CIS_up,gain,positive,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",1405,ATG_CAR_TRANS_dn,loss,negative,ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",116,ATG_CAR_TRANS_up,gain,positive,"Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CAR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR2F1,NR2F1,"nuclear receptor subfamily 2, group F, member 1",1407,ATG_COUP_TF1_TRANS2_dn,loss,negative,ATG_COUP_TF1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2F1,NR2F1,"nuclear receptor subfamily 2, group F, member 1",1357,ATG_COUP_TF1_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1357 -- ATG_COUP_TF1_TRANS2_up,Activation
NR2F2,NR2F2,"nuclear receptor subfamily 2, group F, member 2",1408,ATG_COUP_TF2_TRANS2_dn,loss,negative,ATG_COUP_TF2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2F2,NR2F2,"nuclear receptor subfamily 2, group F, member 2",1350,ATG_COUP_TF2_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1350 -- ATG_COUP_TF2_TRANS2_up,Activation
CREB3,CREB3,cAMP responsive element binding protein 3,1409,ATG_CRE_CIS_dn,loss,negative,ATG_CRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
CREB3,CREB3,cAMP responsive element binding protein 3,69,ATG_CRE_CIS_up,gain,positive,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
NR0B1,NR0B1,"nuclear receptor subfamily 0, group B, member 1",1411,ATG_DAX1_TRANS2_dn,loss,negative,ATG_DAX1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR0B1,NR0B1,"nuclear receptor subfamily 0, group B, member 1",1360,ATG_DAX1_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1360 -- ATG_DAX1_TRANS2_up,Activation
NR1H2,NR1H2,"nuclear receptor subfamily 1, group H, member 2",1412,ATG_DR4_LXR_CIS_dn,loss,negative,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H3,NR1H3,"nuclear receptor subfamily 1, group H, member 3",1412,ATG_DR4_LXR_CIS_dn,loss,negative,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H2,NR1H2,"nuclear receptor subfamily 1, group H, member 2",70,ATG_DR4_LXR_CIS_up,gain,positive,"Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR4_LXR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR1H3,NR1H3,"nuclear receptor subfamily 1, group H, member 3",70,ATG_DR4_LXR_CIS_up,gain,positive,"Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR4_LXR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARA,RARA,"retinoic acid receptor, alpha",1413,ATG_DR5_CIS_dn,loss,negative,ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARB,RARB,"retinoic acid receptor, beta",1413,ATG_DR5_CIS_dn,loss,negative,ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARG,RARG,"retinoic acid receptor, gamma",1413,ATG_DR5_CIS_dn,loss,negative,ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARA,RARA,"retinoic acid receptor, alpha",71,ATG_DR5_CIS_up,gain,positive,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARB,RARB,"retinoic acid receptor, beta",71,ATG_DR5_CIS_up,gain,positive,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARG,RARG,"retinoic acid receptor, gamma",71,ATG_DR5_CIS_up,gain,positive,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
USF1,USF1,upstream transcription factor 1,1424,ATG_E_Box_CIS_dn,loss,negative,ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
USF1,USF1,upstream transcription factor 1,72,ATG_E_Box_CIS_up,gain,positive,"Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E_Box_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-loop-helix protein"".",Activation
E2F1,E2F1,E2F transcription factor 1,1414,ATG_E2F_CIS_dn,loss,negative,ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
E2F1,E2F1,E2F transcription factor 1,73,ATG_E2F_CIS_up,gain,positive,"Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E2F_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""E2F transcription factor"".",Activation
NR2F6,NR2F6,"nuclear receptor subfamily 2, group F, member 6",1415,ATG_EAR2_TRANS2_dn,loss,negative,ATG_EAR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2F6,NR2F6,"nuclear receptor subfamily 2, group F, member 6",1370,ATG_EAR2_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1370 -- ATG_EAR2_TRANS2_up,Activation
EGR1,EGR1,early growth response 1,1416,ATG_EGR_CIS_dn,loss,negative,ATG_EGR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
EGR1,EGR1,early growth response 1,74,ATG_EGR_CIS_up,gain,positive,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""zinc finger"".",Activation
ESR1,ESR1,estrogen receptor 1,1417,ATG_ERa_TRANS_dn,loss,negative,ATG_ERa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESR1,ESR1,estrogen receptor 1,117,ATG_ERa_TRANS_up,gain,positive,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),1418,ATG_ERb_TRANS2_dn,loss,negative,ATG_ERb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),1367,ATG_ERb_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1367 -- ATG_ERb_TRANS2_up,Activation
ESR1,ESR1,estrogen receptor 1,1419,ATG_ERE_CIS_dn,loss,negative,ATG_ERE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESR1,ESR1,estrogen receptor 1,75,ATG_ERE_CIS_up,gain,positive,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESRRA,ESRRA,estrogen-related receptor alpha,1420,ATG_ERRa_TRANS_dn,loss,negative,ATG_ERRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESRRA,ESRRA,estrogen-related receptor alpha,118,ATG_ERRa_TRANS_up,gain,positive,"Data from the assay component ATG_ERRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESRRB,ESRRB,estrogen-related receptor beta,1421,ATG_ERRb_TRANS2_dn,loss,negative,ATG_ERRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESRRB,ESRRB,estrogen-related receptor beta,1355,ATG_ERRb_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1355 -- ATG_ERRb_TRANS2_up,Activation
ESRRG,ESRRG,estrogen-related receptor gamma,1422,ATG_ERRg_TRANS_dn,loss,negative,ATG_ERRg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ESRRG,ESRRG,estrogen-related receptor gamma,119,ATG_ERRg_TRANS_up,gain,positive,"Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ETS1,ETS1,v-ets avian erythroblastosis virus E26 oncogene homolog 1,1423,ATG_Ets_CIS_dn,loss,negative,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ETS1,ETS1,v-ets avian erythroblastosis virus E26 oncogene homolog 1,76,ATG_Ets_CIS_up,gain,positive,"Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ets_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""winged helix-turn-helix"".",Activation
FOXA2,FOXA2,forkhead box A2,1425,ATG_FoxA2_CIS_dn,loss,negative,ATG_FoxA2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
FOXA2,FOXA2,forkhead box A2,77,ATG_FoxA2_CIS_up,gain,positive,"Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxA2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""forkhead box protein"".",Activation
FOXO1,FOXO1,forkhead box O1,1426,ATG_FoxO_CIS_dn,loss,negative,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
FOXO3,FOXO3,forkhead box O3,1426,ATG_FoxO_CIS_dn,loss,negative,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
FOXO1,FOXO1,forkhead box O1,78,ATG_FoxO_CIS_up,gain,positive,"Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxO_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""forkhead box protein"".",Activation
FOXO3,FOXO3,forkhead box O3,78,ATG_FoxO_CIS_up,gain,positive,"Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxO_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""forkhead box protein"".",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",1427,ATG_FXR_TRANS_dn,loss,negative,ATG_FXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",120,ATG_FXR_TRANS_up,gain,positive,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
GATA1,GATA1,GATA binding protein 1 (globin transcription factor 1),1429,ATG_GATA_CIS_dn,loss,negative,ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GATA1,GATA1,GATA binding protein 1 (globin transcription factor 1),79,ATG_GATA_CIS_up,gain,positive,"Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GATA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""GATA proteins"".",Activation
NR6A1,NR6A1,"nuclear receptor subfamily 6, group A, member 1",1430,ATG_GCNF_TRANS2_dn,loss,negative,ATG_GCNF_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR6A1,NR6A1,"nuclear receptor subfamily 6, group A, member 1",1349,ATG_GCNF_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1349 -- ATG_GCNF_TRANS2_up,Activation
GLI1,GLI1,GLI family zinc finger 1,1431,ATG_GLI_CIS_dn,loss,negative,ATG_GLI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GLI1,GLI1,GLI family zinc finger 1,80,ATG_GLI_CIS_up,gain,positive,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""zinc finger"".",Activation
ADORA2A,ADORA2A,adenosine A2a receptor,1745,ATG_GPCR_ADORA2A_TRANS_dn,loss,negative,ATG_GPCR_ADORA2A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADORA2A,ADORA2A,adenosine A2a receptor,1746,ATG_GPCR_ADORA2A_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1746 -- ATG_GPCR_ADORA2A_TRANS_up,Activation
ADORA2B,ADORA2B,adenosine A2b receptor,1747,ATG_GPCR_ADORA2B_TRANS_dn,loss,negative,ATG_GPCR_ADORA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADORA2B,ADORA2B,adenosine A2b receptor,1748,ATG_GPCR_ADORA2B_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1748 -- ATG_GPCR_ADORA2B_TRANS_up,Activation
ADRA1A,ADRA1A,adrenoceptor alpha 1A,1749,ATG_GPCR_ADRA1A_TRANS_dn,loss,negative,ATG_GPCR_ADRA1A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADRA1A,ADRA1A,adrenoceptor alpha 1A,1750,ATG_GPCR_ADRA1A_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1750 -- ATG_GPCR_ADRA1A_TRANS_up,Activation
ADRA2B,ADRA2B,adrenoceptor alpha 2B,1751,ATG_GPCR_ADRA2B_TRANS_dn,loss,negative,ATG_GPCR_ADRA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADRA2B,ADRA2B,adrenoceptor alpha 2B,1752,ATG_GPCR_ADRA2B_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1752 -- ATG_GPCR_ADRA2B_TRANS_up,Activation
ADRB2,ADRB2,"adrenoceptor beta 2, surface",1753,ATG_GPCR_ADRB2_TRANS_dn,loss,negative,ATG_GPCR_ADRB2_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADRB2,ADRB2,"adrenoceptor beta 2, surface",1754,ATG_GPCR_ADRB2_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1754 -- ATG_GPCR_ADRB2_TRANS_up,Activation
ADRB3,ADRB3,adrenoceptor beta 3,1755,ATG_GPCR_ADRB3_TRANS_dn,loss,negative,ATG_GPCR_ADRB3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ADRB3,ADRB3,adrenoceptor beta 3,1756,ATG_GPCR_ADRB3_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1756 -- ATG_GPCR_ADRB3_TRANS_up,Activation
CHRM3,CHRM3,"cholinergic receptor, muscarinic 3",1757,ATG_GPCR_CHRM3_TRANS_dn,loss,negative,ATG_GPCR_CHRM3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
CHRM3,CHRM3,"cholinergic receptor, muscarinic 3",1758,ATG_GPCR_CHRM3_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1758 -- ATG_GPCR_CHRM3_TRANS_up,Activation
DRD1,DRD1,dopamine receptor D1,1759,ATG_GPCR_DRD1_TRANS_dn,loss,negative,ATG_GPCR_DRD1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
DRD1,DRD1,dopamine receptor D1,1760,ATG_GPCR_DRD1_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1760 -- ATG_GPCR_DRD1_TRANS_up,Activation
DRD5,DRD5,dopamine receptor D5,1761,ATG_GPCR_DRD5_TRANS_dn,loss,negative,ATG_GPCR_DRD5_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
DRD5,DRD5,dopamine receptor D5,1762,ATG_GPCR_DRD5_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1762 -- ATG_GPCR_DRD5_TRANS_up,Activation
EDNRA,EDNRA,endothelin receptor type A,1763,ATG_GPCR_EDNRA_TRANS_dn,loss,negative,ATG_GPCR_EDNRA_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
EDNRA,EDNRA,endothelin receptor type A,1764,ATG_GPCR_EDNRA_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1764 -- ATG_GPCR_EDNRA_TRANS_up,Activation
GCGR,GCGR,glucagon receptor,1765,ATG_GPCR_GCGR_TRANS_dn,loss,negative,ATG_GPCR_GCGR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GCGR,GCGR,glucagon receptor,1766,ATG_GPCR_GCGR_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1766 -- ATG_GPCR_GCGR_TRANS_up,Activation
GPBAR1,GPBAR1,G protein-coupled bile acid receptor 1,1767,ATG_GPCR_GPBAR1_TRANS_dn,loss,negative,ATG_GPCR_GPBAR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GPBAR1,GPBAR1,G protein-coupled bile acid receptor 1,1768,ATG_GPCR_GPBAR1_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1768 -- ATG_GPCR_GPBAR1_TRANS_up,Activation
FFAR1,FFAR1,free fatty acid receptor 1,1769,ATG_GPCR_GPR40_TRANS_dn,loss,negative,ATG_GPCR_GPR40_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
FFAR1,FFAR1,free fatty acid receptor 1,1770,ATG_GPCR_GPR40_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1770 -- ATG_GPCR_GPR40_TRANS_up,Activation
GNAQ,GNAQ,G protein subunit alpha q,1771,ATG_GPCR_GQ_TRANS_dn,loss,negative,ATG_GPCR_GQ_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GNAQ,GNAQ,G protein subunit alpha q,1772,ATG_GPCR_GQ_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1772 -- ATG_GPCR_GQ_TRANS_up,Activation
GNAS,GNAS,GNAS complex locus,1775,ATG_GPCR_GS_TRANS_dn,loss,negative,ATG_GPCR_GS_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GNAS,GNAS,GNAS complex locus,1776,ATG_GPCR_GS_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1776 -- ATG_GPCR_GS_TRANS_up,Activation
GNAS,GNAS,GNAS complex locus,1773,ATG_GPCR_GS1_TRANS_dn,loss,negative,ATG_GPCR_GS1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
GNAS,GNAS,GNAS complex locus,1774,ATG_GPCR_GS1_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1774 -- ATG_GPCR_GS1_TRANS_up,Activation
HRH1,HRH1,histamine receptor H1,1777,ATG_GPCR_HRH1_TRANS_dn,loss,negative,ATG_GPCR_HRH1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HRH1,HRH1,histamine receptor H1,1778,ATG_GPCR_HRH1_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1778 -- ATG_GPCR_HRH1_TRANS_up,Activation
HTR6,HTR6,"5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled",1779,ATG_GPCR_HTR6_TRANS_dn,loss,negative,ATG_GPCR_HTR6_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HTR6,HTR6,"5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled",1780,ATG_GPCR_HTR6_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1780 -- ATG_GPCR_HTR6_TRANS_up,Activation
HTR7,HTR7,"5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled",1781,ATG_GPCR_HTR7_TRANS_dn,loss,negative,ATG_GPCR_HTR7_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HTR7,HTR7,"5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled",1782,ATG_GPCR_HTR7_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1782 -- ATG_GPCR_HTR7_TRANS_up,Activation
LPAR4,LPAR4,lysophosphatidic acid receptor 4,1783,ATG_GPCR_LPAR4_TRANS_dn,loss,negative,ATG_GPCR_LPAR4_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
LPAR4,LPAR4,lysophosphatidic acid receptor 4,1784,ATG_GPCR_LPAR4_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1784 -- ATG_GPCR_LPAR4_TRANS_up,Activation
MC1R,MC1R,melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor),1785,ATG_GPCR_MC1R_TRANS_dn,loss,negative,ATG_GPCR_MC1R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MC1R,MC1R,melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor),1786,ATG_GPCR_MC1R_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1786 -- ATG_GPCR_MC1R_TRANS_up,Activation
MC2R,MC2R,melanocortin 2 receptor (adrenocorticotropic hormone),1787,ATG_GPCR_MC2R_TRANS_dn,loss,negative,ATG_GPCR_MC2R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MC2R,MC2R,melanocortin 2 receptor (adrenocorticotropic hormone),1788,ATG_GPCR_MC2R_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1788 -- ATG_GPCR_MC2R_TRANS_up,Activation
MC3R,MC3R,melanocortin 3 receptor,1789,ATG_GPCR_MC3R_TRANS_dn,loss,negative,ATG_GPCR_MC3R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MC3R,MC3R,melanocortin 3 receptor,1790,ATG_GPCR_MC3R_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1790 -- ATG_GPCR_MC3R_TRANS_up,Activation
MC4R,MC4R,melanocortin 4 receptor,1791,ATG_GPCR_MC4R_TRANS_dn,loss,negative,ATG_GPCR_MC4R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MC4R,MC4R,melanocortin 4 receptor,1792,ATG_GPCR_MC4R_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1792 -- ATG_GPCR_MC4R_TRANS_up,Activation
PTGDR,PTGDR,prostaglandin D2 receptor (DP),1793,ATG_GPCR_PTGDR_TRANS_dn,loss,negative,ATG_GPCR_PTGDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PTGDR,PTGDR,prostaglandin D2 receptor (DP),1794,ATG_GPCR_PTGDR_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1794 -- ATG_GPCR_PTGDR_TRANS_up,Activation
PTGIR,PTGIR,prostaglandin I2 (prostacyclin) receptor (IP),1795,ATG_GPCR_PTGIR_TRANS_dn,loss,negative,ATG_GPCR_PTGIR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PTGIR,PTGIR,prostaglandin I2 (prostacyclin) receptor (IP),1796,ATG_GPCR_PTGIR_TRANS_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1796 -- ATG_GPCR_PTGIR_TRANS_up,Activation
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",1433,ATG_GR_TRANS_dn,loss,negative,ATG_GR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",122,ATG_GR_TRANS_up,gain,positive,"Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",1432,ATG_GRE_CIS_dn,loss,negative,ATG_GRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",81,ATG_GRE_CIS_up,gain,positive,"Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
HIF1A,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",1434,ATG_HIF1a_CIS_dn,loss,negative,ATG_HIF1a_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HIF1A,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",82,ATG_HIF1a_CIS_up,gain,positive,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-loop-helix protein"".",Activation
HNF4A,HNF4A,"hepatocyte nuclear factor 4, alpha",1435,ATG_HNF4a_TRANS_dn,loss,negative,ATG_HNF4a_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HNF4A,HNF4A,"hepatocyte nuclear factor 4, alpha",123,ATG_HNF4a_TRANS_up,gain,positive,"Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF4a_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
HNF4G,HNF4G,"hepatocyte nuclear factor 4, gamma",1436,ATG_HNF4g_TRANS2_dn,loss,negative,ATG_HNF4g_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HNF4G,HNF4G,"hepatocyte nuclear factor 4, gamma",1354,ATG_HNF4g_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1354 -- ATG_HNF4g_TRANS2_up,Activation
ONECUT1,ONECUT1,one cut homeobox 1,1437,ATG_HNF6_CIS_dn,loss,negative,ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
ONECUT1,ONECUT1,one cut homeobox 1,83,ATG_HNF6_CIS_up,gain,positive,"Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""homeobox protein"".",Activation
HSF1,HSF1,heat shock transcription factor 1,1439,ATG_HSE_CIS_dn,loss,negative,ATG_HSE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
HSF1,HSF1,heat shock transcription factor 1,84,ATG_HSE_CIS_up,gain,positive,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""heat shock protein"".",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",1440,ATG_IR1_CIS_dn,loss,negative,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",85,ATG_IR1_CIS_up,gain,positive,"Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_IR1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
IRF1,IRF1,interferon regulatory factor 1,1441,ATG_ISRE_CIS_dn,loss,negative,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
IRF1,IRF1,interferon regulatory factor 1,86,ATG_ISRE_CIS_up,gain,positive,"Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ISRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""interferon regulatory factors"".",Activation
NR5A2,NR5A2,"nuclear receptor subfamily 5, group A, member 2",1442,ATG_LRH1_TRANS2_dn,loss,negative,ATG_LRH1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR5A2,NR5A2,"nuclear receptor subfamily 5, group A, member 2",1352,ATG_LRH1_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1352 -- ATG_LRH1_TRANS2_up,Activation
NR1H3,NR1H3,"nuclear receptor subfamily 1, group H, member 3",1443,ATG_LXRa_TRANS_dn,loss,negative,ATG_LXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H3,NR1H3,"nuclear receptor subfamily 1, group H, member 3",125,ATG_LXRa_TRANS_up,gain,positive,"Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR1H2,NR1H2,"nuclear receptor subfamily 1, group H, member 2",1444,ATG_LXRb_TRANS_dn,loss,negative,ATG_LXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1H2,NR1H2,"nuclear receptor subfamily 1, group H, member 2",126,ATG_LXRb_TRANS_up,gain,positive,"Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR3C2,NR3C2,"nuclear receptor subfamily 3, group C, member 2",1446,ATG_MR_TRANS2_dn,loss,negative,ATG_MR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR3C2,NR3C2,"nuclear receptor subfamily 3, group C, member 2",1356,ATG_MR_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1356 -- ATG_MR_TRANS2_up,Activation
MTF1,MTF1,metal-regulatory transcription factor 1,1445,ATG_MRE_CIS_dn,loss,negative,ATG_MRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MTF1,MTF1,metal-regulatory transcription factor 1,91,ATG_MRE_CIS_up,gain,positive,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""zinc finger"".",Activation
MYB,MYB,v-myb avian myeloblastosis viral oncogene homolog,1447,ATG_Myb_CIS_dn,loss,negative,ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MYB,MYB,v-myb avian myeloblastosis viral oncogene homolog,92,ATG_Myb_CIS_up,gain,positive,"Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""MYB proteins"".",Activation
MYC,MYC,v-myc avian myelocytomatosis viral oncogene homolog,1448,ATG_Myc_CIS_dn,loss,negative,ATG_Myc_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
MYC,MYC,v-myc avian myelocytomatosis viral oncogene homolog,93,ATG_Myc_CIS_up,gain,positive,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-loop-helix leucine zipper"".",Activation
NFKB1,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,1458,ATG_NF_kB_CIS_dn,loss,negative,ATG_NF_kB_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NFKB1,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,94,ATG_NF_kB_CIS_up,gain,positive,"Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""NF-kappa B"".",Activation
NFIA,NFIA,nuclear factor I/A,1457,ATG_NFI_CIS_dn,loss,negative,ATG_NFI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NFIA,NFIA,nuclear factor I/A,95,ATG_NFI_CIS_up,gain,positive,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""nuclear factor I"".",Activation
NR4A3,NR4A3,"nuclear receptor subfamily 4, group A, member 3",1459,ATG_NOR1_TRANS2_dn,loss,negative,ATG_NOR1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR4A3,NR4A3,"nuclear receptor subfamily 4, group A, member 3",1358,ATG_NOR1_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1358 -- ATG_NOR1_TRANS2_up,Activation
NRF1,NRF1,nuclear respiratory factor 1,1460,ATG_NRF1_CIS_dn,loss,negative,ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NRF1,NRF1,nuclear respiratory factor 1,96,ATG_NRF1_CIS_up,gain,positive,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""nuclear respiratory factors"".",Activation
NFE2L2,NFE2L2,"nuclear factor, erythroid 2-like 2",1461,ATG_NRF2_ARE_CIS_dn,loss,negative,ATG_NRF2_ARE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NFE2L2,NFE2L2,"nuclear factor, erythroid 2-like 2",97,ATG_NRF2_ARE_CIS_up,gain,positive,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
NR4A1,NR4A1,"nuclear receptor subfamily 4, group A, member 1",1462,ATG_NUR77_TRANS2_dn,loss,negative,ATG_NUR77_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR4A1,NR4A1,"nuclear receptor subfamily 4, group A, member 1",1348,ATG_NUR77_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1348 -- ATG_NUR77_TRANS2_up,Activation
NR4A2,NR4A2,"nuclear receptor subfamily 4, group A, member 2",1463,ATG_NURR1_TRANS_dn,loss,negative,ATG_NURR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR4A2,NR4A2,"nuclear receptor subfamily 4, group A, member 2",131,ATG_NURR1_TRANS_up,gain,positive,"Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
POU2F1,POU2F1,POU class 2 homeobox 1,1464,ATG_Oct_MLP_CIS_dn,loss,negative,ATG_Oct_MLP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
POU2F1,POU2F1,POU class 2 homeobox 1,98,ATG_Oct_MLP_CIS_up,gain,positive,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""POU domain protein"".",Activation
TP53,TP53,tumor protein p53,1465,ATG_p53_CIS_dn,loss,negative,ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TP53,TP53,tumor protein p53,99,ATG_p53_CIS_up,gain,positive,"Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_p53_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",Activation
PAX6,PAX6,paired box 6,1466,ATG_Pax6_CIS_dn,loss,negative,ATG_Pax6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PAX6,PAX6,paired box 6,100,ATG_Pax6_CIS_up,gain,positive,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""paired box protein"".",Activation
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",1467,ATG_PBREM_CIS_dn,loss,negative,ATG_PBREM_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",101,ATG_PBREM_CIS_up,gain,positive,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR2E3,NR2E3,"nuclear receptor subfamily 2, group E, member 3",1468,ATG_PNR_TRANS2_dn,loss,negative,ATG_PNR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2E3,NR2E3,"nuclear receptor subfamily 2, group E, member 3",1351,ATG_PNR_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1351 -- ATG_PNR_TRANS2_up,Activation
PPARA,PPARA,peroxisome proliferator-activated receptor alpha,1469,ATG_PPARa_TRANS_dn,loss,negative,ATG_PPARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARA,PPARA,peroxisome proliferator-activated receptor alpha,132,ATG_PPARa_TRANS_up,gain,positive,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARD,PPARD,peroxisome proliferator-activated receptor delta,1470,ATG_PPARd_TRANS_dn,loss,negative,ATG_PPARd_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARD,PPARD,peroxisome proliferator-activated receptor delta,133,ATG_PPARd_TRANS_up,gain,positive,"Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARd_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,1471,ATG_PPARg_TRANS_dn,loss,negative,ATG_PPARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,134,ATG_PPARg_TRANS_up,gain,positive,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARA,PPARA,peroxisome proliferator-activated receptor alpha,1472,ATG_PPRE_CIS_dn,loss,negative,ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARD,PPARD,peroxisome proliferator-activated receptor delta,1472,ATG_PPRE_CIS_dn,loss,negative,ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,1472,ATG_PPRE_CIS_dn,loss,negative,ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PPARA,PPARA,peroxisome proliferator-activated receptor alpha,102,ATG_PPRE_CIS_up,gain,positive,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARD,PPARD,peroxisome proliferator-activated receptor delta,102,ATG_PPRE_CIS_up,gain,positive,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,102,ATG_PPRE_CIS_up,gain,positive,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PGR,PGR,progesterone receptor,1473,ATG_PR_TRANS2_dn,loss,negative,ATG_PR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PGR,PGR,progesterone receptor-like,1473,ATG_PR_TRANS2_dn,loss,negative,ATG_PR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
PGR,PGR,progesterone receptor,1363,ATG_PR_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1363 -- ATG_PR_TRANS2_up,Activation
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",1475,ATG_PXR_TRANS_dn,loss,negative,ATG_PXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",135,ATG_PXR_TRANS_up,gain,positive,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",1474,ATG_PXRE_CIS_dn,loss,negative,ATG_PXRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",103,ATG_PXRE_CIS_up,gain,positive,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARA,RARA,"retinoic acid receptor, alpha",1476,ATG_RARa_TRANS_dn,loss,negative,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARA,RARA,"retinoic acid receptor, alpha",136,ATG_RARa_TRANS_up,gain,positive,"Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARB,RARB,"retinoic acid receptor, beta",1477,ATG_RARb_TRANS_dn,loss,negative,ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARB,RARB,"retinoic acid receptor, beta",137,ATG_RARb_TRANS_up,gain,positive,"Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RARG,RARG,"retinoic acid receptor, gamma",1478,ATG_RARg_TRANS_dn,loss,negative,ATG_RARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RARG,RARG,"retinoic acid receptor, gamma",138,ATG_RARg_TRANS_up,gain,positive,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR1D1,NR1D1,"nuclear receptor subfamily 1, group D, member 1",1479,ATG_Rev_ERB_A_TRANS2_dn,loss,negative,ATG_Rev_ERB_A_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1D1,NR1D1,"nuclear receptor subfamily 1, group D, member 1",1353,ATG_Rev_ERB_A_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1353 -- ATG_Rev_ERB_A_TRANS2_up,Activation
NR1D2,NR1D2,"nuclear receptor subfamily 1, group D, member 2",1480,ATG_Rev_ERB_B_TRANS2_dn,loss,negative,ATG_Rev_ERB_B_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR1D2,NR1D2,"nuclear receptor subfamily 1, group D, member 2",1361,ATG_Rev_ERB_B_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1361 -- ATG_Rev_ERB_B_TRANS2_up,Activation
RORA,RORA,RAR-related orphan receptor A,1481,ATG_RORa_TRANS2_dn,loss,negative,ATG_RORa_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORA,RORA,RAR-related orphan receptor A,1362,ATG_RORa_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1362 -- ATG_RORa_TRANS2_up,Activation
RORB,RORB,RAR-related orphan receptor B,1482,ATG_RORb_TRANS_dn,loss,negative,ATG_RORb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORB,RORB,RAR-related orphan receptor B,139,ATG_RORb_TRANS_up,gain,positive,"Data from the assay component ATG_RORb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
RORA,RORA,RAR-related orphan receptor A,1483,ATG_RORE_CIS_dn,loss,negative,ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORB,RORB,RAR-related orphan receptor B,1483,ATG_RORE_CIS_dn,loss,negative,ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORC,RORC,RAR-related orphan receptor C,1483,ATG_RORE_CIS_dn,loss,negative,ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORA,RORA,RAR-related orphan receptor A,104,ATG_RORE_CIS_up,gain,positive,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
RORB,RORB,RAR-related orphan receptor B,104,ATG_RORE_CIS_up,gain,positive,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
RORC,RORC,RAR-related orphan receptor C,104,ATG_RORE_CIS_up,gain,positive,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
RORC,RORC,RAR-related orphan receptor C,1484,ATG_RORg_TRANS_dn,loss,negative,ATG_RORg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RORC,RORC,RAR-related orphan receptor C,140,ATG_RORg_TRANS_up,gain,positive,"Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""orphan"".",Activation
RXRA,RXRA,"retinoid X receptor, alpha",1485,ATG_RXRa_TRANS_dn,loss,negative,ATG_RXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RXRA,RXRA,"retinoid X receptor, alpha",141,ATG_RXRa_TRANS_up,gain,positive,"Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RXRB,RXRB,"retinoid X receptor, beta",1486,ATG_RXRb_TRANS_dn,loss,negative,ATG_RXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
RXRB,RXRB,"retinoid X receptor, beta",142,ATG_RXRb_TRANS_up,gain,positive,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RXRG,RXRG,retinoid X receptor gamma,1487,ATG_RXRg_TRANS2_dn,loss,negative,ATG_RXRg_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR5A1,NR5A1,"nuclear receptor subfamily 5, group A, member 1",1488,ATG_SF_1_TRANS2_dn,loss,negative,ATG_SF_1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR5A1,NR5A1,"nuclear receptor subfamily 5, group A, member 1",1365,ATG_SF_1_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1365 -- ATG_SF_1_TRANS2_up,Activation
NR0B2,NR0B2,"nuclear receptor subfamily 0, group B, member 2",1489,ATG_SHP_TRANS2_dn,loss,negative,ATG_SHP_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR0B2,NR0B2,"nuclear receptor subfamily 0, group B, member 2",1366,ATG_SHP_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1366 -- ATG_SHP_TRANS2_up,Activation
SOX1,SOX1,SRY (sex determining region Y)-box 1,1490,ATG_Sox_CIS_dn,loss,negative,ATG_Sox_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
SOX1,SOX1,SRY (sex determining region Y)-box 1,105,ATG_Sox_CIS_up,gain,positive,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""HMG box protein"".",Activation
SP1,SP1,Sp1 transcription factor,1491,ATG_Sp1_CIS_dn,loss,negative,ATG_Sp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
SP1,SP1,Sp1 transcription factor,106,ATG_Sp1_CIS_up,gain,positive,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""zinc finger"".",Activation
SREBF1,SREBF1,sterol regulatory element binding transcription factor 1,1492,ATG_SREBP_CIS_dn,loss,negative,ATG_SREBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
SREBF1,SREBF1,sterol regulatory element binding transcription factor 1,107,ATG_SREBP_CIS_up,gain,positive,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic helix-loop-helix leucine zipper"".",Activation
STAT3,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),1493,ATG_STAT3_CIS_dn,loss,negative,ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
STAT3,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),108,ATG_STAT3_CIS_up,gain,positive,"Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_STAT3_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""stat protein"".",Activation
LEF1,LEF1,lymphoid enhancer-binding factor 1,1496,ATG_TCF_b_cat_CIS_dn,loss,negative,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TCF7,TCF7,"transcription factor 7 (T-cell specific, HMG-box)",1496,ATG_TCF_b_cat_CIS_dn,loss,negative,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TCF7L1,TCF7L1,"transcription factor 7-like 1 (T-cell specific, HMG-box)",1496,ATG_TCF_b_cat_CIS_dn,loss,negative,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TCF7L2,TCF7L2,"transcription factor 7-like 2 (T-cell specific, HMG-box)",1496,ATG_TCF_b_cat_CIS_dn,loss,negative,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
LEF1,LEF1,lymphoid enhancer-binding factor 1,111,ATG_TCF_b_cat_CIS_up,gain,positive,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""HMG box protein"".",Activation
TCF7,TCF7,"transcription factor 7 (T-cell specific, HMG-box)",111,ATG_TCF_b_cat_CIS_up,gain,positive,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""HMG box protein"".",Activation
TCF7L1,TCF7L1,"transcription factor 7-like 1 (T-cell specific, HMG-box)",111,ATG_TCF_b_cat_CIS_up,gain,positive,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""HMG box protein"".",Activation
TCF7L2,TCF7L2,"transcription factor 7-like 2 (T-cell specific, HMG-box)",111,ATG_TCF_b_cat_CIS_up,gain,positive,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""HMG box protein"".",Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",1497,ATG_TGFb_CIS_dn,loss,negative,ATG_TGFb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",112,ATG_TGFb_CIS_up,gain,positive,"Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",Activation
THRA,THRA,"thyroid hormone receptor, alpha",1498,ATG_THRa1_TRANS_dn,loss,negative,ATG_THRa1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
THRA,THRA,"thyroid hormone receptor, alpha",143,ATG_THRa1_TRANS_up,gain,positive,"Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_THRa1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
THRB,THRB,"thyroid hormone receptor, beta",1499,ATG_THRb_TRANS2_dn,loss,negative,ATG_THRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
THRB,THRB,"thyroid hormone receptor, beta",1369,ATG_THRb_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1369 -- ATG_THRb_TRANS2_up,Activation
NR2E1,NR2E1,"nuclear receptor subfamily 2, group E, member 1",1500,ATG_TLX_TRANS2_dn,loss,negative,ATG_TLX_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2E1,NR2E1,"nuclear receptor subfamily 2, group E, member 1",1368,ATG_TLX_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1368 -- ATG_TLX_TRANS2_up,Activation
NR2C1,NR2C1,"nuclear receptor subfamily 2, group C, member 1",1501,ATG_TR2_TRANS2_dn,loss,negative,ATG_TR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2C1,NR2C1,"nuclear receptor subfamily 2, group C, member 1",1371,ATG_TR2_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1371 -- ATG_TR2_TRANS2_up,Activation
NR2C2,NR2C2,"nuclear receptor subfamily 2, group C, member 2",1502,ATG_TR4_TRANS2_dn,loss,negative,ATG_TR4_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
NR2C2,NR2C2,"nuclear receptor subfamily 2, group C, member 2",1359,ATG_TR4_TRANS2_up,gain,positive,inducible reporter assay using RT-PCR and Capillary electrophoresis to monitor transcription factor in HepG2 cell line: AEID1359 -- ATG_TR4_TRANS2_up,Activation
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",1504,ATG_VDR_TRANS_dn,loss,negative,ATG_VDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",144,ATG_VDR_TRANS_up,gain,positive,"Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",1503,ATG_VDRE_CIS_dn,loss,negative,ATG_VDRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",113,ATG_VDRE_CIS_up,gain,positive,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
XBP1,XBP1,X-box binding protein 1,1505,ATG_Xbp1_CIS_dn,loss,negative,ATG_Xbp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,Activation
XBP1,XBP1,X-box binding protein 1,114,ATG_Xbp1_CIS_up,gain,positive,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""basic leucine zipper"".",Activation
SELE,SELE,selectin E,145,BSK_3C_Eselectin_down,loss,negative,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
SELE,SELE,selectin E,146,BSK_3C_Eselectin_up,gain,positive,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",147,BSK_3C_HLADR_down,loss,negative,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",148,BSK_3C_HLADR_up,gain,positive,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
ICAM1,ICAM1,intercellular adhesion molecule 1,149,BSK_3C_ICAM1_down,loss,negative,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
ICAM1,ICAM1,intercellular adhesion molecule 1,150,BSK_3C_ICAM1_up,gain,positive,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,151,BSK_3C_IL8_down,loss,negative,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,152,BSK_3C_IL8_up,gain,positive,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,153,BSK_3C_MCP1_down,loss,negative,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,154,BSK_3C_MCP1_up,gain,positive,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,155,BSK_3C_MIG_down,loss,negative,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,156,BSK_3C_MIG_up,gain,positive,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
THBD,THBD,thrombomodulin,161,BSK_3C_Thrombomodulin_down,loss,negative,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
THBD,THBD,thrombomodulin,162,BSK_3C_Thrombomodulin_up,gain,positive,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",163,BSK_3C_TissueFactor_down,loss,negative,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",164,BSK_3C_TissueFactor_up,gain,positive,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",165,BSK_3C_uPAR_down,loss,negative,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",166,BSK_3C_uPAR_up,gain,positive,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,167,BSK_3C_VCAM1_down,loss,negative,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,168,BSK_3C_VCAM1_up,gain,positive,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
CCL26,CCL26,chemokine (C-C motif) ligand 26,171,BSK_4H_Eotaxin3_down,loss,negative,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL26,CCL26,chemokine (C-C motif) ligand 26,172,BSK_4H_Eotaxin3_up,gain,positive,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,173,BSK_4H_MCP1_down,loss,negative,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,174,BSK_4H_MCP1_up,gain,positive,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
SELP,SELP,"selectin P (granule membrane protein 140kDa, antigen CD62)",175,BSK_4H_Pselectin_down,loss,negative,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
SELP,SELP,"selectin P (granule membrane protein 140kDa, antigen CD62)",176,BSK_4H_Pselectin_up,gain,positive,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",179,BSK_4H_uPAR_down,loss,negative,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",180,BSK_4H_uPAR_up,gain,positive,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,181,BSK_4H_VCAM1_down,loss,negative,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,182,BSK_4H_VCAM1_up,gain,positive,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
KDR,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),183,BSK_4H_VEGFRII_down,loss,negative,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",Activation
KDR,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),184,BSK_4H_VEGFRII_up,gain,positive,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",185,BSK_BE3C_HLADR_down,loss,negative,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",186,BSK_BE3C_HLADR_up,gain,positive,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
IL1A,IL1A,"interleukin 1, alpha",187,BSK_BE3C_IL1a_down,loss,negative,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
IL1A,IL1A,"interleukin 1, alpha",188,BSK_BE3C_IL1a_up,gain,positive,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,189,BSK_BE3C_IP10_down,loss,negative,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,190,BSK_BE3C_IP10_up,gain,positive,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,191,BSK_BE3C_MIG_down,loss,negative,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,192,BSK_BE3C_MIG_up,gain,positive,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),193,BSK_BE3C_MMP1_down,loss,negative,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),194,BSK_BE3C_MMP1_up,gain,positive,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
SERPINE1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",195,BSK_BE3C_PAI1_down,loss,negative,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",Activation
SERPINE1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",196,BSK_BE3C_PAI1_up,gain,positive,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",199,BSK_BE3C_TGFb1_down,loss,negative,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",200,BSK_BE3C_TGFb1_up,gain,positive,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",Activation
PLAT,PLAT,"plasminogen activator, tissue",201,BSK_BE3C_tPA_down,loss,negative,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
PLAT,PLAT,"plasminogen activator, tissue",202,BSK_BE3C_tPA_up,gain,positive,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
PLAU,PLAU,"plasminogen activator, urokinase",203,BSK_BE3C_uPA_down,loss,negative,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
PLAU,PLAU,"plasminogen activator, urokinase",204,BSK_BE3C_uPA_up,gain,positive,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",205,BSK_BE3C_uPAR_down,loss,negative,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",206,BSK_BE3C_uPAR_up,gain,positive,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",207,BSK_CASM3C_HLADR_down,loss,negative,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
HLA-DRA,HLA-DRA,"major histocompatibility complex, class II, DR alpha",208,BSK_CASM3C_HLADR_up,gain,positive,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",Activation
IL6,IL6,interleukin 6,209,BSK_CASM3C_IL6_down,loss,negative,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
IL6,IL6,interleukin 6,210,BSK_CASM3C_IL6_up,gain,positive,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,211,BSK_CASM3C_IL8_down,loss,negative,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,212,BSK_CASM3C_IL8_up,gain,positive,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
LDLR,LDLR,low density lipoprotein receptor,213,BSK_CASM3C_LDLR_down,loss,negative,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",Activation
LDLR,LDLR,low density lipoprotein receptor,214,BSK_CASM3C_LDLR_up,gain,positive,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,215,BSK_CASM3C_MCP1_down,loss,negative,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,216,BSK_CASM3C_MCP1_up,gain,positive,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),217,BSK_CASM3C_MCSF_down,loss,negative,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),218,BSK_CASM3C_MCSF_up,gain,positive,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,219,BSK_CASM3C_MIG_down,loss,negative,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,220,BSK_CASM3C_MIG_up,gain,positive,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
SAA1,SAA1,serum amyloid A1,223,BSK_CASM3C_SAA_down,loss,negative,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",Activation
SAA1,SAA1,serum amyloid A1,224,BSK_CASM3C_SAA_up,gain,positive,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",Activation
THBD,THBD,thrombomodulin,227,BSK_CASM3C_Thrombomodulin_down,loss,negative,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
THBD,THBD,thrombomodulin,228,BSK_CASM3C_Thrombomodulin_up,gain,positive,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",229,BSK_CASM3C_TissueFactor_down,loss,negative,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",230,BSK_CASM3C_TissueFactor_up,gain,positive,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",231,BSK_CASM3C_uPAR_down,loss,negative,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
PLAUR,PLAUR,"plasminogen activator, urokinase receptor",232,BSK_CASM3C_uPAR_up,gain,positive,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,233,BSK_CASM3C_VCAM1_down,loss,negative,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,234,BSK_CASM3C_VCAM1_up,gain,positive,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
COL3A1,COL3A1,"collagen, type III, alpha 1",235,BSK_hDFCGF_CollagenIII_down,loss,negative,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",Activation
COL3A1,COL3A1,"collagen, type III, alpha 1",236,BSK_hDFCGF_CollagenIII_up,gain,positive,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",Activation
EGFR,EGFR,epidermal growth factor receptor,237,BSK_hDFCGF_EGFR_down,loss,negative,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",Activation
EGFR,EGFR,epidermal growth factor receptor,238,BSK_hDFCGF_EGFR_up,gain,positive,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,239,BSK_hDFCGF_IL8_down,loss,negative,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,240,BSK_hDFCGF_IL8_up,gain,positive,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,241,BSK_hDFCGF_IP10_down,loss,negative,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,242,BSK_hDFCGF_IP10_up,gain,positive,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),243,BSK_hDFCGF_MCSF_down,loss,negative,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),244,BSK_hDFCGF_MCSF_up,gain,positive,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,245,BSK_hDFCGF_MIG_down,loss,negative,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,246,BSK_hDFCGF_MIG_up,gain,positive,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),247,BSK_hDFCGF_MMP1_down,loss,negative,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),248,BSK_hDFCGF_MMP1_up,gain,positive,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
SERPINE1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",249,BSK_hDFCGF_PAI1_down,loss,negative,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",Activation
SERPINE1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",250,BSK_hDFCGF_PAI1_up,gain,positive,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",Activation
TIMP1,TIMP1,TIMP metallopeptidase inhibitor 1,255,BSK_hDFCGF_TIMP1_down,loss,negative,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",Activation
TIMP1,TIMP1,TIMP metallopeptidase inhibitor 1,256,BSK_hDFCGF_TIMP1_up,gain,positive,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,257,BSK_hDFCGF_VCAM1_down,loss,negative,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,258,BSK_hDFCGF_VCAM1_up,gain,positive,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
ICAM1,ICAM1,intercellular adhesion molecule 1,259,BSK_KF3CT_ICAM1_down,loss,negative,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
ICAM1,ICAM1,intercellular adhesion molecule 1,260,BSK_KF3CT_ICAM1_up,gain,positive,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
IL1A,IL1A,"interleukin 1, alpha",261,BSK_KF3CT_IL1a_down,loss,negative,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
IL1A,IL1A,"interleukin 1, alpha",262,BSK_KF3CT_IL1a_up,gain,positive,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,263,BSK_KF3CT_IP10_down,loss,negative,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL10,CXCL10,chemokine (C-X-C motif) ligand 10,264,BSK_KF3CT_IP10_up,gain,positive,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,265,BSK_KF3CT_MCP1_down,loss,negative,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,266,BSK_KF3CT_MCP1_up,gain,positive,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
MMP9,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",267,BSK_KF3CT_MMP9_down,loss,negative,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
MMP9,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",268,BSK_KF3CT_MMP9_up,gain,positive,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",271,BSK_KF3CT_TGFb1_down,loss,negative,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",272,BSK_KF3CT_TGFb1_up,gain,positive,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",Activation
TIMP2,TIMP2,TIMP metallopeptidase inhibitor 2,273,BSK_KF3CT_TIMP2_down,loss,negative,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",Activation
TIMP2,TIMP2,TIMP metallopeptidase inhibitor 2,274,BSK_KF3CT_TIMP2_up,gain,positive,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",Activation
PLAU,PLAU,"plasminogen activator, urokinase",275,BSK_KF3CT_uPA_down,loss,negative,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
PLAU,PLAU,"plasminogen activator, urokinase",276,BSK_KF3CT_uPA_up,gain,positive,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",Activation
CD40,CD40,"CD40 molecule, TNF receptor superfamily member 5",277,BSK_LPS_CD40_down,loss,negative,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
CD40,CD40,"CD40 molecule, TNF receptor superfamily member 5",278,BSK_LPS_CD40_up,gain,positive,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
SELE,SELE,selectin E,279,BSK_LPS_Eselectin_down,loss,negative,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
SELE,SELE,selectin E,280,BSK_LPS_Eselectin_up,gain,positive,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
IL1A,IL1A,"interleukin 1, alpha",281,BSK_LPS_IL1a_down,loss,negative,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
IL1A,IL1A,"interleukin 1, alpha",282,BSK_LPS_IL1a_up,gain,positive,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,283,BSK_LPS_IL8_down,loss,negative,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,284,BSK_LPS_IL8_up,gain,positive,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,285,BSK_LPS_MCP1_down,loss,negative,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,286,BSK_LPS_MCP1_up,gain,positive,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),287,BSK_LPS_MCSF_down,loss,negative,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
CSF1,CSF1,colony stimulating factor 1 (macrophage),288,BSK_LPS_MCSF_up,gain,positive,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",Activation
PTGER2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",289,BSK_LPS_PGE2_down,loss,negative,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
PTGER2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",290,BSK_LPS_PGE2_up,gain,positive,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",293,BSK_LPS_TissueFactor_down,loss,negative,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
F3,F3,"coagulation factor III (thromboplastin, tissue factor)",294,BSK_LPS_TissueFactor_up,gain,positive,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",Activation
TNF,TNF,tumor necrosis factor,295,BSK_LPS_TNFa_down,loss,negative,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
TNF,TNF,tumor necrosis factor,296,BSK_LPS_TNFa_up,gain,positive,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,297,BSK_LPS_VCAM1_down,loss,negative,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
VCAM1,VCAM1,vascular cell adhesion molecule 1,298,BSK_LPS_VCAM1_up,gain,positive,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",Activation
CD38,CD38,CD38 molecule,299,BSK_SAg_CD38_down,loss,negative,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",Activation
CD38,CD38,CD38 molecule,300,BSK_SAg_CD38_up,gain,positive,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",Activation
CD40,CD40,"CD40 molecule, TNF receptor superfamily member 5",301,BSK_SAg_CD40_down,loss,negative,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
CD40,CD40,"CD40 molecule, TNF receptor superfamily member 5",302,BSK_SAg_CD40_up,gain,positive,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
CD69,CD69,CD69 molecule,303,BSK_SAg_CD69_down,loss,negative,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
CD69,CD69,CD69 molecule,304,BSK_SAg_CD69_up,gain,positive,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",Activation
SELE,SELE,selectin E,305,BSK_SAg_Eselectin_down,loss,negative,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
SELE,SELE,selectin E,306,BSK_SAg_Eselectin_up,gain,positive,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,307,BSK_SAg_IL8_down,loss,negative,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CXCL8,CXCL8,chemokine (C-X-C motif) ligand 8,308,BSK_SAg_IL8_up,gain,positive,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,309,BSK_SAg_MCP1_down,loss,negative,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CCL2,CCL2,chemokine (C-C motif) ligand 2,310,BSK_SAg_MCP1_up,gain,positive,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,311,BSK_SAg_MIG_down,loss,negative,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
CXCL9,CXCL9,chemokine (C-X-C motif) ligand 9,312,BSK_SAg_MIG_up,gain,positive,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",Activation
11-deoxycortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",890,CEETOX_H295R_11DCORT_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycortisol in H295R cell line: AEID890 -- CEETOX_H295R_11DCORT_dn,inhibition
11-deoxycortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",890,CEETOX_H295R_11DCORT_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycortisol in H295R cell line: AEID890 -- CEETOX_H295R_11DCORT_dn,inhibition
11-deoxycortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2142,CEETOX_H295R_11DCORT_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
11-deoxycortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2142,CEETOX_H295R_11DCORT_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
11-deoxycortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2143,CEETOX_H295R_11DCORT_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
11-deoxycortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2143,CEETOX_H295R_11DCORT_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
11-deoxycortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",891,CEETOX_H295R_11DCORT_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycortisol in H295R cell line: AEID891 -- CEETOX_H295R_11DCORT_up,Activation
11-deoxycortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",891,CEETOX_H295R_11DCORT_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycortisol in H295R cell line: AEID891 -- CEETOX_H295R_11DCORT_up,Activation
androstenedione,AR,androgen receptor,896,CEETOX_H295R_ANDR_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Androstenedione in H295R cell line: AEID896 -- CEETOX_H295R_ANDR_dn,inhibition
androstenedione,AR,androgen receptor,2148,CEETOX_H295R_ANDR_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
androstenedione,AR,androgen receptor,2149,CEETOX_H295R_ANDR_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
androstenedione,AR,androgen receptor,897,CEETOX_H295R_ANDR_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Androstenedione in H295R cell line: AEID897 -- CEETOX_H295R_ANDR_up,Activation
corticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",898,CEETOX_H295R_CORTIC_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Corticosterone in H295R cell line: AEID898 -- CEETOX_H295R_CORTIC_dn,inhibition
corticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",898,CEETOX_H295R_CORTIC_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Corticosterone in H295R cell line: AEID898 -- CEETOX_H295R_CORTIC_dn,inhibition
corticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2150,CEETOX_H295R_CORTIC_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
corticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2150,CEETOX_H295R_CORTIC_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
corticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2151,CEETOX_H295R_CORTIC_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
corticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2151,CEETOX_H295R_CORTIC_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Corticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
corticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",899,CEETOX_H295R_CORTIC_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Corticosterone in H295R cell line: AEID899 -- CEETOX_H295R_CORTIC_up,Activation
corticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",899,CEETOX_H295R_CORTIC_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Corticosterone in H295R cell line: AEID899 -- CEETOX_H295R_CORTIC_up,Activation
cortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",900,CEETOX_H295R_CORTISOL_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Cortisol in H295R cell line: AEID900 -- CEETOX_H295R_CORTISOL_dn,inhibition
cortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",900,CEETOX_H295R_CORTISOL_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Cortisol in H295R cell line: AEID900 -- CEETOX_H295R_CORTISOL_dn,inhibition
cortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2152,CEETOX_H295R_CORTISOL_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
cortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2152,CEETOX_H295R_CORTISOL_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
cortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2153,CEETOX_H295R_CORTISOL_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
cortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2153,CEETOX_H295R_CORTISOL_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Cortisol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
cortisol,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",901,CEETOX_H295R_CORTISOL_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Cortisol in H295R cell line: AEID901 -- CEETOX_H295R_CORTISOL_up,Activation
cortisol,NR3C2,"nuclear receptor subfamily 3, group C, member 2",901,CEETOX_H295R_CORTISOL_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Cortisol in H295R cell line: AEID901 -- CEETOX_H295R_CORTISOL_up,Activation
11-Deoxycorticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",904,CEETOX_H295R_DOC_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycorticosterone in H295R cell line: AEID904 -- CEETOX_H295R_DOC_dn,inhibition
11-Deoxycorticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",904,CEETOX_H295R_DOC_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycorticosterone in H295R cell line: AEID904 -- CEETOX_H295R_DOC_dn,inhibition
11-Deoxycorticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2156,CEETOX_H295R_DOC_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
11-Deoxycorticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2156,CEETOX_H295R_DOC_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
11-Deoxycorticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",2157,CEETOX_H295R_DOC_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
11-Deoxycorticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",2157,CEETOX_H295R_DOC_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 11-Deoxycorticosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
11-Deoxycorticosterone,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",905,CEETOX_H295R_DOC_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycorticosterone in H295R cell line: AEID905 -- CEETOX_H295R_DOC_up,Activation
11-Deoxycorticosterone,NR3C2,"nuclear receptor subfamily 3, group C, member 2",905,CEETOX_H295R_DOC_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 11-Deoxycorticosterone in H295R cell line: AEID905 -- CEETOX_H295R_DOC_up,Activation
estradiol,ESR1,estrogen receptor 1,906,CEETOX_H295R_ESTRADIOL_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Estradiol in H295R cell line: AEID906 -- CEETOX_H295R_ESTRADIOL_dn,inhibition
estradiol,ESR2,estrogen receptor 2 (ER beta),906,CEETOX_H295R_ESTRADIOL_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Estradiol in H295R cell line: AEID906 -- CEETOX_H295R_ESTRADIOL_dn,inhibition
estradiol,ESR1,estrogen receptor 1,2158,CEETOX_H295R_ESTRADIOL_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
estradiol,ESR2,estrogen receptor 2 (ER beta),2158,CEETOX_H295R_ESTRADIOL_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
estradiol,ESR1,estrogen receptor 1,2159,CEETOX_H295R_ESTRADIOL_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
estradiol,ESR2,estrogen receptor 2 (ER beta),2159,CEETOX_H295R_ESTRADIOL_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Estradiol in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
estradiol,ESR1,estrogen receptor 1,907,CEETOX_H295R_ESTRADIOL_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Estradiol in H295R cell line: AEID907 -- CEETOX_H295R_ESTRADIOL_up,Activation
estradiol,ESR2,estrogen receptor 2 (ER beta),907,CEETOX_H295R_ESTRADIOL_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Estradiol in H295R cell line: AEID907 -- CEETOX_H295R_ESTRADIOL_up,Activation
estrone,ESR1,estrogen receptor 1,908,CEETOX_H295R_ESTRONE_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Estrone in H295R cell line: AEID908 -- CEETOX_H295R_ESTRONE_dn,inhibition
estrone,ESR2,estrogen receptor 2 (ER beta),908,CEETOX_H295R_ESTRONE_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Estrone in H295R cell line: AEID908 -- CEETOX_H295R_ESTRONE_dn,inhibition
estrone,ESR1,estrogen receptor 1,2160,CEETOX_H295R_ESTRONE_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
estrone,ESR2,estrogen receptor 2 (ER beta),2160,CEETOX_H295R_ESTRONE_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
estrone,ESR1,estrogen receptor 1,2161,CEETOX_H295R_ESTRONE_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
estrone,ESR2,estrogen receptor 2 (ER beta),2161,CEETOX_H295R_ESTRONE_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Estrone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
estrone,ESR1,estrogen receptor 1,909,CEETOX_H295R_ESTRONE_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Estrone in H295R cell line: AEID909 -- CEETOX_H295R_ESTRONE_up,Activation
estrone,ESR2,estrogen receptor 2 (ER beta),909,CEETOX_H295R_ESTRONE_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Estrone in H295R cell line: AEID909 -- CEETOX_H295R_ESTRONE_up,Activation
17alpha-hydroxypregnenolone,PGR,progesterone receptor,892,CEETOX_H295R_OHPREG_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 17alpha-hydroxypregnenolone in H295R cell line: AEID892 -- CEETOX_H295R_OHPREG_dn,inhibition
17alpha-hydroxypregnenolone,NR1I2,"nuclear receptor subfamily 1, group I, member 2",2144,CEETOX_H295R_OHPREG_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
17alpha-hydroxypregnenolone,NR1I2,"nuclear receptor subfamily 1, group I, member 2",2145,CEETOX_H295R_OHPREG_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
17alpha-hydroxypregnenolone,PGR,progesterone receptor,893,CEETOX_H295R_OHPREG_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 17alpha-hydroxypregnenolone in H295R cell line: AEID893 -- CEETOX_H295R_OHPREG_up,Activation
17alpha-hydroxypregnenolone,PGR,progesterone receptor,894,CEETOX_H295R_OHPROG_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor 17alpha-hydroxyprogesterone in H295R cell line: AEID894 -- CEETOX_H295R_OHPROG_dn,inhibition
17alpha-hydroxypregnenolone,NR1I2,"nuclear receptor subfamily 1, group I, member 2",2146,CEETOX_H295R_OHPROG_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
17alpha-hydroxypregnenolone,NR1I2,"nuclear receptor subfamily 1, group I, member 2",2147,CEETOX_H295R_OHPROG_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
17alpha-hydroxypregnenolone,PGR,progesterone receptor,895,CEETOX_H295R_OHPROG_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor 17alpha-hydroxyprogesterone in H295R cell line: AEID895 -- CEETOX_H295R_OHPROG_up,Activation
progesterone,PGR,progesterone receptor,912,CEETOX_H295R_PROG_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Progesterone in H295R cell line: AEID912 -- CEETOX_H295R_PROG_dn,inhibition
progesterone,PGR,progesterone receptor-like,912,CEETOX_H295R_PROG_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Progesterone in H295R cell line: AEID912 -- CEETOX_H295R_PROG_dn,inhibition
progesterone,PGR,progesterone receptor,2164,CEETOX_H295R_PROG_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
progesterone,PGR,progesterone receptor-like,2164,CEETOX_H295R_PROG_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
progesterone,PGR,progesterone receptor,2165,CEETOX_H295R_PROG_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
progesterone,PGR,progesterone receptor-like,2165,CEETOX_H295R_PROG_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Progesterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
progesterone,PGR,progesterone receptor,913,CEETOX_H295R_PROG_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Progesterone in H295R cell line: AEID913 -- CEETOX_H295R_PROG_up,Activation
progesterone,PGR,progesterone receptor-like,913,CEETOX_H295R_PROG_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Progesterone in H295R cell line: AEID913 -- CEETOX_H295R_PROG_up,Activation
testosterone,AR,androgen receptor,914,CEETOX_H295R_TESTO_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Testosterone in H295R cell line: AEID914 -- CEETOX_H295R_TESTO_dn,inhibition
testosterone,ESR1,estrogen receptor 1,914,CEETOX_H295R_TESTO_dn,loss,negative,inducible reporter assay using HPLC-MS-MS to monitor Testosterone in H295R cell line: AEID914 -- CEETOX_H295R_TESTO_dn,inhibition
testosterone,AR,androgen receptor,2166,CEETOX_H295R_TESTO_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
testosterone,ESR1,estrogen receptor 1,2166,CEETOX_H295R_TESTO_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
testosterone,ESR2,estrogen receptor 2 (ER beta),2166,CEETOX_H295R_TESTO_noMTC_dn,loss,negative,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); a decrease in biosynthesis was curve-fit in the positive direction",inhibition
testosterone,AR,androgen receptor,2167,CEETOX_H295R_TESTO_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
testosterone,ESR1,estrogen receptor 1,2167,CEETOX_H295R_TESTO_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
testosterone,ESR2,estrogen receptor 2 (ER beta),2167,CEETOX_H295R_TESTO_noMTC_up,gain,positive,"assay system using HPLC-MS-MS to monitor synthesis of Testosterone in H295R cell line at 48hr of chemical exposure, without filtering concentrations for maximum tolerated concentration (MTC); an increase in biosynthesis was curve-fit in the positive direction",Activation
testosterone,AR,androgen receptor,915,CEETOX_H295R_TESTO_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Testosterone in H295R cell line: AEID915 -- CEETOX_H295R_TESTO_up,Activation
testosterone,ESR1,estrogen receptor 1,915,CEETOX_H295R_TESTO_up,gain,positive,inducible reporter assay using HPLC-MS-MS to monitor Testosterone in H295R cell line: AEID915 -- CEETOX_H295R_TESTO_up,Activation
ABCB1,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",1627,CLD_ABCB1_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1627 -- CLD_ABCB1_24hr,Activation
ABCB1,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",1643,CLD_ABCB1_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1643 -- CLD_ABCB1_48hr,Activation
ABCB1,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",1611,CLD_ABCB1_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1611 -- CLD_ABCB1_6hr,Activation
ABCB11,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",1628,CLD_ABCB11_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1628 -- CLD_ABCB11_24hr,Activation
ABCB11,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",1644,CLD_ABCB11_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1644 -- CLD_ABCB11_48hr,Activation
ABCB11,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",1612,CLD_ABCB11_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1612 -- CLD_ABCB11_6hr,Activation
ABCG2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",1629,CLD_ABCG2_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1629 -- CLD_ABCG2_24hr,Activation
ABCG2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",1645,CLD_ABCG2_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1645 -- CLD_ABCG2_48hr,Activation
ABCG2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",1613,CLD_ABCG2_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1613 -- CLD_ABCG2_6hr,Activation
ACTA1,ACTA1,"actin, alpha 1, skeletal muscle",1630,CLD_ACTIN_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1630 -- CLD_ACTIN_24hr,Activation
ACTB,ACTB,"actin, beta",1630,CLD_ACTIN_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1630 -- CLD_ACTIN_24hr,Activation
ACTG1,ACTG1,actin gamma 1,1630,CLD_ACTIN_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1630 -- CLD_ACTIN_24hr,Activation
ACTA1,ACTA1,"actin, alpha 1, skeletal muscle",1646,CLD_ACTIN_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1646 -- CLD_ACTIN_48hr,Activation
ACTB,ACTB,"actin, beta",1646,CLD_ACTIN_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1646 -- CLD_ACTIN_48hr,Activation
ACTG1,ACTG1,actin gamma 1,1646,CLD_ACTIN_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1646 -- CLD_ACTIN_48hr,Activation
ACTA1,ACTA1,"actin, alpha 1, skeletal muscle",1614,CLD_ACTIN_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1614 -- CLD_ACTIN_6hr,Activation
ACTB,ACTB,"actin, beta",1614,CLD_ACTIN_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1614 -- CLD_ACTIN_6hr,Activation
ACTG1,ACTG1,actin gamma 1,1614,CLD_ACTIN_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1614 -- CLD_ACTIN_6hr,Activation
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",1631,CLD_CYP1A1_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1631 -- CLD_CYP1A1_24hr,Activation
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",1647,CLD_CYP1A1_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1647 -- CLD_CYP1A1_48hr,Activation
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",1615,CLD_CYP1A1_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1615 -- CLD_CYP1A1_6hr,Activation
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",1632,CLD_CYP1A2_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1632 -- CLD_CYP1A2_24hr,Activation
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",1648,CLD_CYP1A2_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1648 -- CLD_CYP1A2_48hr,Activation
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",1616,CLD_CYP1A2_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1616 -- CLD_CYP1A2_6hr,Activation
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",1633,CLD_CYP2B6_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1633 -- CLD_CYP2B6_24hr,Activation
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",1649,CLD_CYP2B6_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1649 -- CLD_CYP2B6_48hr,Activation
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",1617,CLD_CYP2B6_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1617 -- CLD_CYP2B6_6hr,Activation
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",1634,CLD_CYP2C19_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1634 -- CLD_CYP2C19_24hr,Activation
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",1650,CLD_CYP2C19_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1650 -- CLD_CYP2C19_48hr,Activation
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",1618,CLD_CYP2C19_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1618 -- CLD_CYP2C19_6hr,Activation
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",1635,CLD_CYP2C9_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1635 -- CLD_CYP2C9_24hr,Activation
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",1651,CLD_CYP2C9_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1651 -- CLD_CYP2C9_48hr,Activation
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",1619,CLD_CYP2C9_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1619 -- CLD_CYP2C9_6hr,Activation
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",1636,CLD_CYP3A4_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1636 -- CLD_CYP3A4_24hr,Activation
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",1652,CLD_CYP3A4_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1652 -- CLD_CYP3A4_48hr,Activation
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",1620,CLD_CYP3A4_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1620 -- CLD_CYP3A4_6hr,Activation
GAPDH,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,1637,CLD_GAPDH_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1637 -- CLD_GAPDH_24hr,Activation
GAPDH,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,1653,CLD_GAPDH_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1653 -- CLD_GAPDH_48hr,Activation
GAPDH,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,1621,CLD_GAPDH_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1621 -- CLD_GAPDH_6hr,Activation
GSTA2,GSTA2,glutathione S-transferase alpha 2,1638,CLD_GSTA2_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1638 -- CLD_GSTA2_24hr,Activation
GSTA2,GSTA2,glutathione S-transferase alpha 2,1654,CLD_GSTA2_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1654 -- CLD_GSTA2_48hr,Activation
GSTA2,GSTA2,glutathione S-transferase alpha 2,1622,CLD_GSTA2_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1622 -- CLD_GSTA2_6hr,Activation
HMGCS2,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),1639,CLD_HMGCS2_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1639 -- CLD_HMGCS2_24hr,Activation
HMGCS2,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),1655,CLD_HMGCS2_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1655 -- CLD_HMGCS2_48hr,Activation
HMGCS2,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),1623,CLD_HMGCS2_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1623 -- CLD_HMGCS2_6hr,Activation
SLCO1B1,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",1640,CLD_SLCO1B1_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1640 -- CLD_SLCO1B1_24hr,Activation
SLCO1B1,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",1656,CLD_SLCO1B1_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1656 -- CLD_SLCO1B1_48hr,Activation
SLCO1B1,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",1624,CLD_SLCO1B1_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1624 -- CLD_SLCO1B1_6hr,Activation
SULT2A1,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",1641,CLD_SULT2A_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1641 -- CLD_SULT2A_24hr,Activation
SULT2A1,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",1657,CLD_SULT2A_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1657 -- CLD_SULT2A_48hr,Activation
SULT2A1,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",1625,CLD_SULT2A_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1625 -- CLD_SULT2A_6hr,Activation
UGT1A1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",1642,CLD_UGT1A1_24hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1642 -- CLD_UGT1A1_24hr,Activation
UGT1A1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",1658,CLD_UGT1A1_48hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1658 -- CLD_UGT1A1_48hr,Activation
UGT1A1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",1626,CLD_UGT1A1_6hr,gain,positive,inducible reporter assay using Quantitative Nuclease Protection Assay (qNPA) to monitor mRNA in hepatocyte cell line: AEID1626 -- CLD_UGT1A1_6hr,Activation
ABCB1,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",916,LTEA_HepaRG_ABCB1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ABCB1,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",917,LTEA_HepaRG_ABCB1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ABCB11,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",918,LTEA_HepaRG_ABCB11_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ABCB11,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",919,LTEA_HepaRG_ABCB11_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ABCC2,ABCC2,"ATP-binding cassette, sub-family C (CFTR/MRP), member 2",920,LTEA_HepaRG_ABCC2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ABCC2,ABCC2,"ATP-binding cassette, sub-family C (CFTR/MRP), member 2",921,LTEA_HepaRG_ABCC2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ABCC3,ABCC3,"ATP-binding cassette, sub-family C (CFTR/MRP), member 3",922,LTEA_HepaRG_ABCC3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ABCC3,ABCC3,"ATP-binding cassette, sub-family C (CFTR/MRP), member 3",923,LTEA_HepaRG_ABCC3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ABCG2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",924,LTEA_HepaRG_ABCG2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ABCG2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",925,LTEA_HepaRG_ABCG2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ACLY,ACLY,ATP citrate lyase,926,LTEA_HepaRG_ACLY_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ACLY,ACLY,ATP citrate lyase,927,LTEA_HepaRG_ACLY_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ACOX1,ACOX1,"acyl-CoA oxidase 1, palmitoyl",928,LTEA_HepaRG_ACOX1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ACOX1,ACOX1,"acyl-CoA oxidase 1, palmitoyl",929,LTEA_HepaRG_ACOX1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ADK,ADK,adenosine kinase,930,LTEA_HepaRG_ADK_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ADK,ADK,adenosine kinase,931,LTEA_HepaRG_ADK_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
AFP,AFP,alpha-fetoprotein,932,LTEA_HepaRG_AFP_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
AFP,AFP,alpha-fetoprotein,933,LTEA_HepaRG_AFP_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ALPP,ALPP,"alkaline phosphatase, placental",934,LTEA_HepaRG_ALPP_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ALPP,ALPP,"alkaline phosphatase, placental",935,LTEA_HepaRG_ALPP_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
APOA5,APOA5,apolipoprotein A-V,936,LTEA_HepaRG_APOA5_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
APOA5,APOA5,apolipoprotein A-V,937,LTEA_HepaRG_APOA5_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
BAD,BAD,BCL2-associated agonist of cell death,938,LTEA_HepaRG_BAD_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
BAD,BAD,BCL2-associated agonist of cell death,939,LTEA_HepaRG_BAD_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
BAX,BAX,BCL2-associated X protein,940,LTEA_HepaRG_BAX_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
BAX,BAX,BCL2-associated X protein,941,LTEA_HepaRG_BAX_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
BCL2,BCL2,B-cell CLL/lymphoma 2,942,LTEA_HepaRG_BCL2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
BCL2,BCL2,B-cell CLL/lymphoma 2,943,LTEA_HepaRG_BCL2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
BCL2L11,BCL2L11,BCL2-like 11 (apoptosis facilitator),944,LTEA_HepaRG_BCL2L11_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
BCL2L11,BCL2L11,BCL2-like 11 (apoptosis facilitator),945,LTEA_HepaRG_BCL2L11_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
BID,BID,BH3 interacting domain death agonist,946,LTEA_HepaRG_BID_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
BID,BID,BH3 interacting domain death agonist,947,LTEA_HepaRG_BID_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",948,LTEA_HepaRG_CASP3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",949,LTEA_HepaRG_CASP3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CASP8,CASP8,"caspase 8, apoptosis-related cysteine peptidase",950,LTEA_HepaRG_CASP8_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CASP8,CASP8,"caspase 8, apoptosis-related cysteine peptidase",951,LTEA_HepaRG_CASP8_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CAT,CAT,catalase,952,LTEA_HepaRG_CAT_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CAT,CAT,catalase,953,LTEA_HepaRG_CAT_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CCND1,CCND1,cyclin D1,954,LTEA_HepaRG_CCND1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CCND1,CCND1,cyclin D1,955,LTEA_HepaRG_CCND1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CCND2,CCND2,cyclin D2,956,LTEA_HepaRG_CCND2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CCND2,CCND2,cyclin D2,957,LTEA_HepaRG_CCND2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CDKN1A,CDKN1A,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",958,LTEA_HepaRG_CDKN1A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CDKN1A,CDKN1A,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",959,LTEA_HepaRG_CDKN1A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CFLAR,CFLAR,CASP8 and FADD-like apoptosis regulator,960,LTEA_HepaRG_CFLAR_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CFLAR,CFLAR,CASP8 and FADD-like apoptosis regulator,961,LTEA_HepaRG_CFLAR_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",962,LTEA_HepaRG_CYP1A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",963,LTEA_HepaRG_CYP1A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",964,LTEA_HepaRG_CYP1A2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",965,LTEA_HepaRG_CYP1A2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",1398,LTEA_HepaRG_CYP24A1_1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",1399,LTEA_HepaRG_CYP24A1_1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",966,LTEA_HepaRG_CYP24A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",967,LTEA_HepaRG_CYP24A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",968,LTEA_HepaRG_CYP2B6_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",969,LTEA_HepaRG_CYP2B6_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",970,LTEA_HepaRG_CYP2C19_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",971,LTEA_HepaRG_CYP2C19_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP2C8,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",972,LTEA_HepaRG_CYP2C8_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP2C8,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",973,LTEA_HepaRG_CYP2C8_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",974,LTEA_HepaRG_CYP2C9_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",975,LTEA_HepaRG_CYP2C9_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP2E1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",976,LTEA_HepaRG_CYP2E1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP2E1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",977,LTEA_HepaRG_CYP2E1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",978,LTEA_HepaRG_CYP3A4_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",979,LTEA_HepaRG_CYP3A4_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP3A5,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",980,LTEA_HepaRG_CYP3A5_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP3A5,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",981,LTEA_HepaRG_CYP3A5_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP3A7,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",982,LTEA_HepaRG_CYP3A7_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP3A7,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",983,LTEA_HepaRG_CYP3A7_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP4A11,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",984,LTEA_HepaRG_CYP4A11_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP4A11,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",985,LTEA_HepaRG_CYP4A11_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP4A22,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",986,LTEA_HepaRG_CYP4A22_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP4A22,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",987,LTEA_HepaRG_CYP4A22_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
CYP7A1,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",988,LTEA_HepaRG_CYP7A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
CYP7A1,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",989,LTEA_HepaRG_CYP7A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
DDIT3,DDIT3,DNA-damage-inducible transcript 3,990,LTEA_HepaRG_DDIT3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
DDIT3,DDIT3,DNA-damage-inducible transcript 3,991,LTEA_HepaRG_DDIT3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
EGF,EGF,epidermal growth factor,992,LTEA_HepaRG_EGF_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
EGF,EGF,epidermal growth factor,993,LTEA_HepaRG_EGF_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
EGR1,EGR1,early growth response 1,994,LTEA_HepaRG_EGR1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
EGR1,EGR1,early growth response 1,995,LTEA_HepaRG_EGR1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
EZR,EZR,ezrin,996,LTEA_HepaRG_EZR_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
EZR,EZR,ezrin,997,LTEA_HepaRG_EZR_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FABP1,FABP1,"fatty acid binding protein 1, liver",998,LTEA_HepaRG_FABP1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FABP1,FABP1,"fatty acid binding protein 1, liver",999,LTEA_HepaRG_FABP1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FAS,FAS,Fas cell surface death receptor,1000,LTEA_HepaRG_FAS_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FAS,FAS,Fas cell surface death receptor,1001,LTEA_HepaRG_FAS_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FASN,FASN,fatty acid synthase,1002,LTEA_HepaRG_FASN_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FASN,FASN,fatty acid synthase,1003,LTEA_HepaRG_FASN_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FMO3,FMO3,flavin containing monooxygenase 3,1004,LTEA_HepaRG_FMO3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FMO3,FMO3,flavin containing monooxygenase 3,1005,LTEA_HepaRG_FMO3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FOXO1,FOXO1,forkhead box O1,1006,LTEA_HepaRG_FOXO1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FOXO1,FOXO1,forkhead box O1,1007,LTEA_HepaRG_FOXO1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
FOXO3,FOXO3,forkhead box O3,1008,LTEA_HepaRG_FOXO3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
FOXO3,FOXO3,forkhead box O3,1009,LTEA_HepaRG_FOXO3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GADD45A,GADD45A,"growth arrest and DNA-damage-inducible, alpha",1010,LTEA_HepaRG_GADD45A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GADD45A,GADD45A,"growth arrest and DNA-damage-inducible, alpha",1011,LTEA_HepaRG_GADD45A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GADD45B,GADD45B,"growth arrest and DNA-damage-inducible, beta",1012,LTEA_HepaRG_GADD45B_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GADD45B,GADD45B,"growth arrest and DNA-damage-inducible, beta",1013,LTEA_HepaRG_GADD45B_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GADD45G,GADD45G,"growth arrest and DNA-damage-inducible, gamma",1014,LTEA_HepaRG_GADD45G_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GADD45G,GADD45G,"growth arrest and DNA-damage-inducible, gamma",1015,LTEA_HepaRG_GADD45G_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GCLC,GCLC,"glutamate-cysteine ligase, catalytic subunit",1016,LTEA_HepaRG_GCLC_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GCLC,GCLC,"glutamate-cysteine ligase, catalytic subunit",1017,LTEA_HepaRG_GCLC_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GCLM,GCLM,"glutamate-cysteine ligase, modifier subunit",1018,LTEA_HepaRG_GCLM_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GCLM,GCLM,"glutamate-cysteine ligase, modifier subunit",1019,LTEA_HepaRG_GCLM_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ACTB,ACTB,"actin, beta",1020,LTEA_HepaRG_GE_ACTB_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ACTB,ACTB,"actin, beta",1021,LTEA_HepaRG_GE_ACTB_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GAPDH,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,1022,LTEA_HepaRG_GE_GAPDH_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GAPDH,GAPDH,glyceraldehyde-3-phosphate dehydrogenase,1023,LTEA_HepaRG_GE_GAPDH_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
POLR2A,POLR2A,"polymerase (RNA) II (DNA directed) polypeptide A, 220kDa",1024,LTEA_HepaRG_GE_POLR2A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
POLR2A,POLR2A,"polymerase (RNA) II (DNA directed) polypeptide A, 220kDa",1025,LTEA_HepaRG_GE_POLR2A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GSTA2,GSTA2,glutathione S-transferase alpha 2,1026,LTEA_HepaRG_GSTA2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GSTA2,GSTA2,glutathione S-transferase alpha 2,1027,LTEA_HepaRG_GSTA2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
GSTM3,GSTM3,glutathione S-transferase mu 3 (brain),1028,LTEA_HepaRG_GSTM3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
GSTM3,GSTM3,glutathione S-transferase mu 3 (brain),1029,LTEA_HepaRG_GSTM3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
HGF,HGF,hepatocyte growth factor (hepapoietin A; scatter factor),1030,LTEA_HepaRG_HGF_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
HGF,HGF,hepatocyte growth factor (hepapoietin A; scatter factor),1031,LTEA_HepaRG_HGF_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
HIF1A,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",1032,LTEA_HepaRG_HIF1A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
HIF1A,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",1033,LTEA_HepaRG_HIF1A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
HMGCS2,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),1034,LTEA_HepaRG_HMGCS2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
HMGCS2,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),1035,LTEA_HepaRG_HMGCS2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
HSPA1A,HSPA1A,heat shock 70kDa protein 1A,1036,LTEA_HepaRG_HSPA1A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
HSPA1A,HSPA1A,heat shock 70kDa protein 1A,1037,LTEA_HepaRG_HSPA1A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
ICAM1,ICAM1,intercellular adhesion molecule 1,1038,LTEA_HepaRG_ICAM1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
ICAM1,ICAM1,intercellular adhesion molecule 1,1039,LTEA_HepaRG_ICAM1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
IGF1,IGF1,insulin-like growth factor 1 (somatomedin C),1040,LTEA_HepaRG_IGF1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
IGF1,IGF1,insulin-like growth factor 1 (somatomedin C),1041,LTEA_HepaRG_IGF1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
IGFBP1,IGFBP1,insulin-like growth factor binding protein 1,1042,LTEA_HepaRG_IGFBP1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
IGFBP1,IGFBP1,insulin-like growth factor binding protein 1,1043,LTEA_HepaRG_IGFBP1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
IL6,IL6,interleukin 6,1044,LTEA_HepaRG_IL6_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
IL6,IL6,interleukin 6,1045,LTEA_HepaRG_IL6_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
IL6R,IL6R,interleukin 6 receptor,1046,LTEA_HepaRG_IL6R_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
IL6R,IL6R,interleukin 6 receptor,1047,LTEA_HepaRG_IL6R_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
JUN,JUN,jun proto-oncogene,1048,LTEA_HepaRG_JUN_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
JUN,JUN,jun proto-oncogene,1049,LTEA_HepaRG_JUN_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
KCNK1,KCNK1,"potassium channel, subfamily K, member 1",1050,LTEA_HepaRG_KCNK1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
KCNK1,KCNK1,"potassium channel, subfamily K, member 1",1051,LTEA_HepaRG_KCNK1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
KLK3,KLK3,kallikrein-related peptidase 3,1392,LTEA_HepaRG_KLK3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
KLK3,KLK3,kallikrein-related peptidase 3,1393,LTEA_HepaRG_KLK3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
KRT19,KRT19,keratin 19,1052,LTEA_HepaRG_KRT19_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
KRT19,KRT19,keratin 19,1053,LTEA_HepaRG_KRT19_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
LIPC,LIPC,"lipase, hepatic",1054,LTEA_HepaRG_LIPC_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
LIPC,LIPC,"lipase, hepatic",1055,LTEA_HepaRG_LIPC_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
LPL,LPL,lipoprotein lipase,1056,LTEA_HepaRG_LPL_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
LPL,LPL,lipoprotein lipase,1057,LTEA_HepaRG_LPL_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
MIR122,MIR122,microRNA 122,1058,LTEA_HepaRG_MIR122_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
MIR122,MIR122,microRNA 122,1059,LTEA_HepaRG_MIR122_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),1396,LTEA_HepaRG_MMP1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),1397,LTEA_HepaRG_MMP1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
MMP10,MMP10,matrix metallopeptidase 10 (stromelysin 2),1060,LTEA_HepaRG_MMP10_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
MMP10,MMP10,matrix metallopeptidase 10 (stromelysin 2),1061,LTEA_HepaRG_MMP10_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
MMP3,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",1062,LTEA_HepaRG_MMP3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
MMP3,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",1063,LTEA_HepaRG_MMP3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
MYC,MYC,v-myc avian myelocytomatosis viral oncogene homolog,1064,LTEA_HepaRG_MYC_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
MYC,MYC,v-myc avian myelocytomatosis viral oncogene homolog,1065,LTEA_HepaRG_MYC_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
NFE2L2,NFE2L2,"nuclear factor, erythroid 2-like 2",1066,LTEA_HepaRG_NFE2L2_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
NFE2L2,NFE2L2,"nuclear factor, erythroid 2-like 2",1067,LTEA_HepaRG_NFE2L2_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
NFKB1,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,1068,LTEA_HepaRG_NFKB1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
NFKB1,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,1069,LTEA_HepaRG_NFKB1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
NQO1,NQO1,"NAD(P)H dehydrogenase, quinone 1",1070,LTEA_HepaRG_NQO1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
NQO1,NQO1,"NAD(P)H dehydrogenase, quinone 1",1071,LTEA_HepaRG_NQO1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
PDK4,PDK4,"pyruvate dehydrogenase kinase, isozyme 4",1072,LTEA_HepaRG_PDK4_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
PDK4,PDK4,"pyruvate dehydrogenase kinase, isozyme 4",1073,LTEA_HepaRG_PDK4_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
PEG10,PEG10,paternally expressed 10,1074,LTEA_HepaRG_PEG10_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
PEG10,PEG10,paternally expressed 10,1075,LTEA_HepaRG_PEG10_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
PPP2R4,PPP2R4,"protein phosphatase 2A activator, regulatory subunit 4",1076,LTEA_HepaRG_PPP2R4_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
PPP2R4,PPP2R4,"protein phosphatase 2A activator, regulatory subunit 4",1077,LTEA_HepaRG_PPP2R4_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
PTEN,PTEN,phosphatase and tensin homolog,1078,LTEA_HepaRG_PTEN_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
PTEN,PTEN,phosphatase and tensin homolog,1079,LTEA_HepaRG_PTEN_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SDHB,SDHB,"succinate dehydrogenase complex, subunit B, iron sulfur (Ip)",1080,LTEA_HepaRG_SDHB_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SDHB,SDHB,"succinate dehydrogenase complex, subunit B, iron sulfur (Ip)",1081,LTEA_HepaRG_SDHB_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SLC10A1,SLC10A1,"solute carrier family 10 (sodium/bile acid cotransporter), member 1",1394,LTEA_HepaRG_SLC10A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SLC10A1,SLC10A1,"solute carrier family 10 (sodium/bile acid cotransporter), member 1",1395,LTEA_HepaRG_SLC10A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SLC22A1,SLC22A1,"solute carrier family 22 (organic cation transporter), member 1",1082,LTEA_HepaRG_SLC22A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SLC22A1,SLC22A1,"solute carrier family 22 (organic cation transporter), member 1",1083,LTEA_HepaRG_SLC22A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SLC22A6,SLC22A6,"solute carrier family 22 (organic anion transporter), member 6",1390,LTEA_HepaRG_SLC22A6_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SLC22A6,SLC22A6,"solute carrier family 22 (organic anion transporter), member 6",1391,LTEA_HepaRG_SLC22A6_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SLCO1B1,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",1084,LTEA_HepaRG_SLCO1B1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SLCO1B1,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",1085,LTEA_HepaRG_SLCO1B1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
STAT3,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),1086,LTEA_HepaRG_STAT3_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
STAT3,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),1087,LTEA_HepaRG_STAT3_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
SULT2A1,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",1088,LTEA_HepaRG_SULT2A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
SULT2A1,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",1089,LTEA_HepaRG_SULT2A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
TGFA,TGFA,"transforming growth factor, alpha",1090,LTEA_HepaRG_TGFA_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
TGFA,TGFA,"transforming growth factor, alpha",1091,LTEA_HepaRG_TGFA_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
TGFB1,TGFB1,"transforming growth factor, beta 1",1092,LTEA_HepaRG_TGFB1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
TGFB1,TGFB1,"transforming growth factor, beta 1",1093,LTEA_HepaRG_TGFB1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
THRSP,THRSP,thyroid hormone responsive,1094,LTEA_HepaRG_THRSP_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
THRSP,THRSP,thyroid hormone responsive,1095,LTEA_HepaRG_THRSP_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
TIMP1,TIMP1,TIMP metallopeptidase inhibitor 1,1096,LTEA_HepaRG_TIMP1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
TIMP1,TIMP1,TIMP metallopeptidase inhibitor 1,1097,LTEA_HepaRG_TIMP1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
TNFRSF1A,TNFRSF1A,"tumor necrosis factor receptor superfamily, member 1A",1098,LTEA_HepaRG_TNFRSF1A_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
TNFRSF1A,TNFRSF1A,"tumor necrosis factor receptor superfamily, member 1A",1099,LTEA_HepaRG_TNFRSF1A_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
TP53,TP53,tumor protein p53,1100,LTEA_HepaRG_TP53_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
TP53,TP53,tumor protein p53,1101,LTEA_HepaRG_TP53_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
UGT1A1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",1102,LTEA_HepaRG_UGT1A1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
UGT1A1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",1103,LTEA_HepaRG_UGT1A1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
UGT1A6,UGT1A6,"UDP glucuronosyltransferase 1 family, polypeptide A6",1104,LTEA_HepaRG_UGT1A6_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
UGT1A6,UGT1A6,"UDP glucuronosyltransferase 1 family, polypeptide A6",1105,LTEA_HepaRG_UGT1A6_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
XBP1,XBP1,X-box binding protein 1,1106,LTEA_HepaRG_XBP1_dn,loss,negative,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,inhibition
XBP1,XBP1,X-box binding protein 1,1107,LTEA_HepaRG_XBP1_up,gain,positive,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,Activation
NA,NA,"luciferase [Cloning vector pGL3-Basic, complete sequence]",1848,NCCT_QuantiLum_inhib_2_dn,loss,positive,protein single format assay using NA cell line: AEID1848 -- NCCT_QuantiLum_inhib_2_dn,inhibition
NA,NA,"luciferase [Cloning vector pGL3-Basic, complete sequence]",1510,NCCT_QuantiLum_inhib_dn,loss,positive,protein single format assay using NA cell line: AEID1510 -- NCCT_QuantiLum_inhib_dn,inhibition
Tpo,Tpo,thyroid peroxidase,1508,NCCT_TPO_AUR_dn,loss,positive,protein single format assay using rat thyroid gland cell line: AEID1508 -- NCCT_TPO_AUR_dn,inhibition
TPO,TPO,thyroid peroxidase,1824,NCCT_TPO_GUA_dn,loss,positive,protein single format assay using pig thyroid gland cell line: AEID1824 -- NCCT_TPO_GUA_dn,inhibition
DIO1,DIO1,iodothyronine deiodinase 1,2309,NHEERL_MED_hDIO1_dn,loss,dn,"Data from the assay component NHEERL_MED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, NHEERL_MED_hDIO1_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",inhibition
SLC5A5,SLC5A5,solute carrier family 5 member 5,2037,NIS_RAIU_inhibition,loss,positive,enzyme reporter assay using MicroBeta radioactivity plate reader to monitor enzyme in HEK293T cell line: AEID2037 -- NIS_RAIU_inhibition,inhibition
CYP19A1,CYP19A1,"cytochrome P450, family 19, subfamily A, polypeptide 1",319,NVS_ADME_hCYP19A1,loss,positive,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""steroidogenesis-related"".",inhibition
CYP19A1,CYP19A1,"cytochrome P450, family 19, subfamily A, polypeptide 1",320,NVS_ADME_hCYP19A1_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""steroidogenesis-related"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",321,NVS_ADME_hCYP1A1,loss,positive,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP1A1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",322,NVS_ADME_hCYP1A1_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",323,NVS_ADME_hCYP1A2,loss,positive,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP1A2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",324,NVS_ADME_hCYP1A2_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP1B1,CYP1B1,"cytochrome P450, family 1, subfamily B, polypeptide 1",325,NVS_ADME_hCYP1B1,loss,positive,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP1B1,CYP1B1,"cytochrome P450, family 1, subfamily B, polypeptide 1",326,NVS_ADME_hCYP1B1_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2A6,CYP2A6,"cytochrome P450, family 2, subfamily A, polypeptide 6",327,NVS_ADME_hCYP2A6,loss,positive,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2A6,CYP2A6,"cytochrome P450, family 2, subfamily A, polypeptide 6",328,NVS_ADME_hCYP2A6_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",329,NVS_ADME_hCYP2B6,loss,positive,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2B6,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",330,NVS_ADME_hCYP2B6_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2C18,CYP2C18,"cytochrome P450, family 2, subfamily C, polypeptide 18",331,NVS_ADME_hCYP2C18,loss,positive,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2C18,CYP2C18,"cytochrome P450, family 2, subfamily C, polypeptide 18",332,NVS_ADME_hCYP2C18_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",333,NVS_ADME_hCYP2C19,loss,positive,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2C19,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",334,NVS_ADME_hCYP2C19_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2C8,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",335,NVS_ADME_hCYP2C8,loss,positive,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2C8,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",336,NVS_ADME_hCYP2C8_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",337,NVS_ADME_hCYP2C9,loss,positive,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2C9,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",338,NVS_ADME_hCYP2C9_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2D6,CYP2D6,"cytochrome P450, family 2, subfamily D, polypeptide 6",339,NVS_ADME_hCYP2D6,loss,positive,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2D6,CYP2D6,"cytochrome P450, family 2, subfamily D, polypeptide 6",340,NVS_ADME_hCYP2D6_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2E1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",341,NVS_ADME_hCYP2E1,loss,positive,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2E1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",342,NVS_ADME_hCYP2E1_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP2J2,CYP2J2,"cytochrome P450, family 2, subfamily J, polypeptide 2",343,NVS_ADME_hCYP2J2,loss,positive,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP2J2,CYP2J2,"cytochrome P450, family 2, subfamily J, polypeptide 2",344,NVS_ADME_hCYP2J2_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",345,NVS_ADME_hCYP3A4,loss,positive,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP3A4,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",346,NVS_ADME_hCYP3A4_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP3A5,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",347,NVS_ADME_hCYP3A5,loss,positive,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP3A5,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",348,NVS_ADME_hCYP3A5_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CYP4F12,CYP4F12,"cytochrome P450, family 4, subfamily F, polypeptide 12",349,NVS_ADME_hCYP4F12,loss,positive,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
CYP4F12,CYP4F12,"cytochrome P450, family 4, subfamily F, polypeptide 12",350,NVS_ADME_hCYP4F12_Activator,gain,negative,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp1a1,Cyp1a1,"cytochrome P450, family 1, subfamily a, polypeptide 1",351,NVS_ADME_rCYP1A1,loss,positive,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp1a1,Cyp1a1,"cytochrome P450, family 1, subfamily a, polypeptide 1",352,NVS_ADME_rCYP1A1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp1a2,Cyp1a2,"cytochrome P450, family 1, subfamily a, polypeptide 2",353,NVS_ADME_rCYP1A2,loss,positive,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp1a2,Cyp1a2,"cytochrome P450, family 1, subfamily a, polypeptide 2",354,NVS_ADME_rCYP1A2_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2a1,Cyp2a1,"cytochrome P450, family 2, subfamily a, polypeptide 1",355,NVS_ADME_rCYP2A1,loss,positive,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2a1,Cyp2a1,"cytochrome P450, family 2, subfamily a, polypeptide 1",356,NVS_ADME_rCYP2A1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2a2,Cyp2a2,"cytochrome P450, family 2, subfamily a, polypeptide 2",357,NVS_ADME_rCYP2A2,loss,positive,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2a2,Cyp2a2,"cytochrome P450, family 2, subfamily a, polypeptide 2",358,NVS_ADME_rCYP2A2_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2b1,Cyp2b1,"cytochrome P450, family 2, subfamily b, polypeptide 1",359,NVS_ADME_rCYP2B1,loss,positive,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2b1,Cyp2b1,"cytochrome P450, family 2, subfamily b, polypeptide 1",360,NVS_ADME_rCYP2B1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2c11,Cyp2c11,"cytochrome P450, subfamily 2, polypeptide 11",361,NVS_ADME_rCYP2C11,loss,positive,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2c11,Cyp2c11,"cytochrome P450, subfamily 2, polypeptide 11",362,NVS_ADME_rCYP2C11_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2c12,Cyp2c12,"cytochrome P450, family 2, subfamily c, polypeptide 12",363,NVS_ADME_rCYP2C12,loss,positive,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2c12,Cyp2c12,"cytochrome P450, family 2, subfamily c, polypeptide 12",364,NVS_ADME_rCYP2C12_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2c13,Cyp2c13,"cytochrome P450, family 2, subfamily c, polypeptide 13",365,NVS_ADME_rCYP2C13,loss,positive,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2c13,Cyp2c13,"cytochrome P450, family 2, subfamily c, polypeptide 13",366,NVS_ADME_rCYP2C13_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2c6v1,Cyp2c6v1,"cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1",367,NVS_ADME_rCYP2C6,loss,positive,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2c6v1,Cyp2c6v1,"cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1",368,NVS_ADME_rCYP2C6_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2d1,Cyp2d1,"cytochrome P450, family 2, subfamily d, polypeptide 1",369,NVS_ADME_rCYP2D1,loss,positive,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2d1,Cyp2d1,"cytochrome P450, family 2, subfamily d, polypeptide 1",370,NVS_ADME_rCYP2D1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2d2,Cyp2d2,"cytochrome P450, family 2, subfamily d, polypeptide 2",371,NVS_ADME_rCYP2D2,loss,positive,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2d2,Cyp2d2,"cytochrome P450, family 2, subfamily d, polypeptide 2",372,NVS_ADME_rCYP2D2_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp2e1,Cyp2e1,"cytochrome P450, family 2, subfamily e, polypeptide 1",373,NVS_ADME_rCYP2E1,loss,positive,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp2e1,Cyp2e1,"cytochrome P450, family 2, subfamily e, polypeptide 1",374,NVS_ADME_rCYP2E1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp3a23/3a1,Cyp3a23/3a1,"cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1",375,NVS_ADME_rCYP3A1,loss,positive,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp3a23/3a1,Cyp3a23/3a1,"cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1",376,NVS_ADME_rCYP3A1_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Cyp3a2,Cyp3a2,"cytochrome P450, family 3, subfamily a, polypeptide 2",377,NVS_ADME_rCYP3A2,loss,positive,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",inhibition
Cyp3a2,Cyp3a2,"cytochrome P450, family 3, subfamily a, polypeptide 2",378,NVS_ADME_rCYP3A2_Activator,gain,negative,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ABL1,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",379,NVS_ENZ_hAbl,loss,positive,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
ABL1,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",380,NVS_ENZ_hAbl_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ACHE,ACHE,acetylcholinesterase (Yt blood group),381,NVS_ENZ_hAChE,loss,positive,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"".",inhibition
ACHE,ACHE,acetylcholinesterase (Yt blood group),382,NVS_ENZ_hAChE_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ACP1,ACP1,"acid phosphatase 1, soluble",383,NVS_ENZ_hACP1,loss,positive,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""acid phosphatase"".",inhibition
ACP1,ACP1,"acid phosphatase 1, soluble",384,NVS_ENZ_hACP1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""acid phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
AKT1,AKT1,v-akt murine thymoma viral oncogene homolog 1,385,NVS_ENZ_hAKT1,loss,positive,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
AKT1,AKT1,v-akt murine thymoma viral oncogene homolog 1,386,NVS_ENZ_hAKT1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
AKT2,AKT2,v-akt murine thymoma viral oncogene homolog 2,387,NVS_ENZ_hAKT2,loss,positive,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
AKT2,AKT2,v-akt murine thymoma viral oncogene homolog 2,388,NVS_ENZ_hAKT2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
AKT3,AKT3,v-akt murine thymoma viral oncogene homolog 3,389,NVS_ENZ_hAKT3,loss,positive,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
AKT3,AKT3,v-akt murine thymoma viral oncogene homolog 3,390,NVS_ENZ_hAKT3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PRKAA1,PRKAA1,"protein kinase, AMP-activated, alpha 1 catalytic subunit",391,NVS_ENZ_hAMPKa1,loss,positive,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PRKAA1,PRKAA1,"protein kinase, AMP-activated, alpha 1 catalytic subunit",392,NVS_ENZ_hAMPKa1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
AURKA,AURKA,aurora kinase A,393,NVS_ENZ_hAurA,loss,positive,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
AURKA,AURKA,aurora kinase A,394,NVS_ENZ_hAurA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
BACE1,BACE1,beta-site APP-cleaving enzyme 1,395,NVS_ENZ_hBACE,loss,positive,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"".",inhibition
BACE1,BACE1,beta-site APP-cleaving enzyme 1,396,NVS_ENZ_hBACE_Activator,gain,negative,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
BTK,BTK,Bruton agammaglobulinemia tyrosine kinase,397,NVS_ENZ_hBTK,loss,positive,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
BTK,BTK,Bruton agammaglobulinemia tyrosine kinase,398,NVS_ENZ_hBTK_Activator,gain,negative,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP1,CASP1,"caspase 1, apoptosis-related cysteine peptidase",399,NVS_ENZ_hCASP1,loss,positive,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP1,CASP1,"caspase 1, apoptosis-related cysteine peptidase",400,NVS_ENZ_hCASP1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP10,CASP10,"caspase 10, apoptosis-related cysteine peptidase",401,NVS_ENZ_hCASP10,loss,positive,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP10,CASP10,"caspase 10, apoptosis-related cysteine peptidase",402,NVS_ENZ_hCASP10_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP2,CASP2,"caspase 2, apoptosis-related cysteine peptidase",403,NVS_ENZ_hCASP2,loss,positive,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP2,CASP2,"caspase 2, apoptosis-related cysteine peptidase",404,NVS_ENZ_hCASP2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",405,NVS_ENZ_hCASP3,loss,positive,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",406,NVS_ENZ_hCASP3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP4,CASP4,"caspase 4, apoptosis-related cysteine peptidase",407,NVS_ENZ_hCASP4,loss,positive,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP4,CASP4,"caspase 4, apoptosis-related cysteine peptidase",408,NVS_ENZ_hCASP4_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP5,CASP5,"caspase 5, apoptosis-related cysteine peptidase",409,NVS_ENZ_hCASP5,loss,positive,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP5,CASP5,"caspase 5, apoptosis-related cysteine peptidase",410,NVS_ENZ_hCASP5_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CASP8,CASP8,"caspase 8, apoptosis-related cysteine peptidase",411,NVS_ENZ_hCASP8,loss,positive,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",inhibition
CASP8,CASP8,"caspase 8, apoptosis-related cysteine peptidase",412,NVS_ENZ_hCASP8_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CDK2,CDK2,cyclin-dependent kinase 2,413,NVS_ENZ_hCDK2,loss,positive,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CDK2,CDK2,cyclin-dependent kinase 2,414,NVS_ENZ_hCDK2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CDK6,CDK6,cyclin-dependent kinase 6,415,NVS_ENZ_hCDK6,loss,positive,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CDK6,CDK6,cyclin-dependent kinase 6,416,NVS_ENZ_hCDK6_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CHEK1,CHEK1,checkpoint kinase 1,417,NVS_ENZ_hCHK1,loss,positive,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CHEK1,CHEK1,checkpoint kinase 1,418,NVS_ENZ_hCHK1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CSNK1A1,CSNK1A1,"casein kinase 1, alpha 1",419,NVS_ENZ_hCK1a,loss,positive,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CSNK1A1,CSNK1A1,"casein kinase 1, alpha 1",420,NVS_ENZ_hCK1a_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CSNK1D,CSNK1D,"casein kinase 1, delta",421,NVS_ENZ_hCK1D,loss,positive,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CSNK1D,CSNK1D,"casein kinase 1, delta",422,NVS_ENZ_hCK1D_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CSNK2A1,CSNK2A1,"casein kinase 2, alpha 1 polypeptide",423,NVS_ENZ_hCK2a2b2,loss,positive,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CSNK2A1,CSNK2A1,"casein kinase 2, alpha 1 polypeptide",424,NVS_ENZ_hCK2a2b2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CSF1R,CSF1R,colony stimulating factor 1 receptor,425,NVS_ENZ_hCSF1R,loss,positive,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
CSF1R,CSF1R,colony stimulating factor 1 receptor,426,NVS_ENZ_hCSF1R_Activator,gain,negative,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
DUSP3,DUSP3,dual specificity phosphatase 3,427,NVS_ENZ_hDUSP3,loss,positive,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",inhibition
DUSP3,DUSP3,dual specificity phosphatase 3,428,NVS_ENZ_hDUSP3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
DYRK1A,DYRK1A,dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A,599,NVS_ENZ_hDYRK1a,loss,positive,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""dual-specific kinase"".",inhibition
DYRK1A,DYRK1A,dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A,600,NVS_ENZ_hDYRK1a_Activator,gain,negative,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""dual-specific kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
EGFR,EGFR,epidermal growth factor receptor,429,NVS_ENZ_hEGFR,loss,positive,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
EGFR,EGFR,epidermal growth factor receptor,430,NVS_ENZ_hEGFR_Activator,gain,negative,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ELANE,ELANE,"elastase, neutrophil expressed",431,NVS_ENZ_hElastase,loss,positive,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",inhibition
ELANE,ELANE,"elastase, neutrophil expressed",432,NVS_ENZ_hElastase_Activator,gain,negative,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
EPHA1,EPHA1,EPH receptor A1,433,NVS_ENZ_hEphA1,loss,positive,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
EPHA1,EPHA1,EPH receptor A1,434,NVS_ENZ_hEphA1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
EPHA2,EPHA2,EPH receptor A2,435,NVS_ENZ_hEphA2,loss,positive,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
EPHA2,EPHA2,EPH receptor A2,436,NVS_ENZ_hEphA2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
EPHB1,EPHB1,EPH receptor B1,437,NVS_ENZ_hEphB1,loss,positive,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
EPHB1,EPHB1,EPH receptor B1,438,NVS_ENZ_hEphB1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
EPHB2,EPHB2,EPH receptor B2,439,NVS_ENZ_hEphB2,loss,positive,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
EPHB2,EPHB2,EPH receptor B2,440,NVS_ENZ_hEphB2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
BCHE,BCHE,butyrylcholinesterase,441,NVS_ENZ_hES,loss,positive,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""pseudocholinesterase"".",inhibition
BCHE,BCHE,butyrylcholinesterase,442,NVS_ENZ_hES_Activator,gain,negative,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""pseudocholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
FGFR1,FGFR1,fibroblast growth factor receptor 1,443,NVS_ENZ_hFGFR1,loss,positive,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
FGFR1,FGFR1,fibroblast growth factor receptor 1,444,NVS_ENZ_hFGFR1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
FGFR3,FGFR3,fibroblast growth factor receptor 3,445,NVS_ENZ_hFGFR3,loss,positive,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
FGFR3,FGFR3,fibroblast growth factor receptor 3,446,NVS_ENZ_hFGFR3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
FYN,FYN,"FYN proto-oncogene, Src family tyrosine kinase",447,NVS_ENZ_hFyn,loss,positive,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
FYN,FYN,"FYN proto-oncogene, Src family tyrosine kinase",448,NVS_ENZ_hFyn_Activator,gain,negative,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
GSK3B,GSK3B,glycogen synthase kinase 3 beta,449,NVS_ENZ_hGSK3b,loss,positive,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
GSK3B,GSK3B,glycogen synthase kinase 3 beta,450,NVS_ENZ_hGSK3b_Activator,gain,negative,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
HDAC3,HDAC3,histone deacetylase 3,451,NVS_ENZ_hHDAC3,loss,positive,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"".",inhibition
HDAC3,HDAC3,histone deacetylase 3,452,NVS_ENZ_hHDAC3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
HDAC6,HDAC6,histone deacetylase 6,453,NVS_ENZ_hHDAC6,loss,positive,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"".",inhibition
HDAC6,HDAC6,histone deacetylase 6,454,NVS_ENZ_hHDAC6_Activator,gain,negative,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
IGF1R,IGF1R,insulin-like growth factor 1 receptor,455,NVS_ENZ_hIGF1R,loss,positive,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
IGF1R,IGF1R,insulin-like growth factor 1 receptor,456,NVS_ENZ_hIGF1R_Activator,gain,negative,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CHUK,CHUK,conserved helix-loop-helix ubiquitous kinase,457,NVS_ENZ_hIKKa,loss,positive,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
CHUK,CHUK,conserved helix-loop-helix ubiquitous kinase,458,NVS_ENZ_hIKKa_Activator,gain,negative,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
INSR,INSR,insulin receptor,459,NVS_ENZ_hInsR,loss,positive,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
INSR,INSR,insulin receptor,460,NVS_ENZ_hInsR_Activator,gain,negative,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
IRAK4,IRAK4,interleukin-1 receptor-associated kinase 4,461,NVS_ENZ_hIRAK4,loss,positive,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
IRAK4,IRAK4,interleukin-1 receptor-associated kinase 4,462,NVS_ENZ_hIRAK4_Activator,gain,negative,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
JAK2,JAK2,Janus kinase 2,463,NVS_ENZ_hJak2,loss,positive,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
JAK2,JAK2,Janus kinase 2,464,NVS_ENZ_hJak2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPK9,MAPK9,mitogen-activated protein kinase 9,465,NVS_ENZ_hJNK2,loss,positive,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPK9,MAPK9,mitogen-activated protein kinase 9,466,NVS_ENZ_hJNK2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
LCK,LCK,"LCK proto-oncogene, Src family tyrosine kinase",467,NVS_ENZ_hLck,loss,positive,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
LCK,LCK,"LCK proto-oncogene, Src family tyrosine kinase",468,NVS_ENZ_hLck_Activator,gain,negative,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
LYN,LYN,"LYN proto-oncogene, Src family tyrosine kinase",469,NVS_ENZ_hLynA,loss,positive,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
LYN,LYN,"LYN proto-oncogene, Src family tyrosine kinase",470,NVS_ENZ_hLynA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
LYN,LYN,"LYN proto-oncogene, Src family tyrosine kinase",471,NVS_ENZ_hLynB,loss,positive,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
LYN,LYN,"LYN proto-oncogene, Src family tyrosine kinase",472,NVS_ENZ_hLynB_Activator,gain,negative,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPK1,MAPK1,mitogen-activated protein kinase 1,473,NVS_ENZ_hMAPK1,loss,positive,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPK1,MAPK1,mitogen-activated protein kinase 1,474,NVS_ENZ_hMAPK1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPK11,MAPK11,mitogen-activated protein kinase 11,475,NVS_ENZ_hMAPK11,loss,positive,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPK11,MAPK11,mitogen-activated protein kinase 11,476,NVS_ENZ_hMAPK11_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPK3,MAPK3,mitogen-activated protein kinase 3,477,NVS_ENZ_hMAPK3,loss,positive,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPK3,MAPK3,mitogen-activated protein kinase 3,478,NVS_ENZ_hMAPK3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPKAPK2,MAPKAPK2,mitogen-activated protein kinase-activated protein kinase 2,479,NVS_ENZ_hMAPKAPK2,loss,positive,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPKAPK2,MAPKAPK2,mitogen-activated protein kinase-activated protein kinase 2,480,NVS_ENZ_hMAPKAPK2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MAPKAPK5,MAPKAPK5,mitogen-activated protein kinase-activated protein kinase 5,481,NVS_ENZ_hMAPKAPK5,loss,positive,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MAPKAPK5,MAPKAPK5,mitogen-activated protein kinase-activated protein kinase 5,482,NVS_ENZ_hMAPKAPK5_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MARK1,MARK1,MAP/microtubule affinity-regulating kinase 1,483,NVS_ENZ_hMARK1,loss,positive,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
MARK1,MARK1,MAP/microtubule affinity-regulating kinase 1,484,NVS_ENZ_hMARK1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MET,MET,"MET proto-oncogene, receptor tyrosine kinase",485,NVS_ENZ_hMet,loss,positive,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
MET,MET,"MET proto-oncogene, receptor tyrosine kinase",486,NVS_ENZ_hMet_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),487,NVS_ENZ_hMMP1,loss,positive,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),488,NVS_ENZ_hMMP1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP13,MMP13,matrix metallopeptidase 13 (collagenase 3),489,NVS_ENZ_hMMP13,loss,positive,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP13,MMP13,matrix metallopeptidase 13 (collagenase 3),490,NVS_ENZ_hMMP13_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP2,MMP2,"matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)",491,NVS_ENZ_hMMP2,loss,positive,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP2,MMP2,"matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)",492,NVS_ENZ_hMMP2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP3,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",493,NVS_ENZ_hMMP3,loss,positive,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP3,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",494,NVS_ENZ_hMMP3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP7,MMP7,"matrix metallopeptidase 7 (matrilysin, uterine)",495,NVS_ENZ_hMMP7,loss,positive,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP7,MMP7,"matrix metallopeptidase 7 (matrilysin, uterine)",496,NVS_ENZ_hMMP7_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MMP9,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",497,NVS_ENZ_hMMP9,loss,positive,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",inhibition
MMP9,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",498,NVS_ENZ_hMMP9_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
RPS6KA5,RPS6KA5,"ribosomal protein S6 kinase, 90kDa, polypeptide 5",499,NVS_ENZ_hMsk1,loss,positive,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
RPS6KA5,RPS6KA5,"ribosomal protein S6 kinase, 90kDa, polypeptide 5",500,NVS_ENZ_hMsk1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
NEK2,NEK2,NIMA-related kinase 2,501,NVS_ENZ_hNEK2,loss,positive,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
NEK2,NEK2,NIMA-related kinase 2,502,NVS_ENZ_hNEK2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PAK2,PAK2,p21 protein (Cdc42/Rac)-activated kinase 2,503,NVS_ENZ_hPAK2,loss,positive,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PAK2,PAK2,p21 protein (Cdc42/Rac)-activated kinase 2,504,NVS_ENZ_hPAK2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PAK4,PAK4,p21 protein (Cdc42/Rac)-activated kinase 4,505,NVS_ENZ_hPAK4,loss,positive,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PAK4,PAK4,p21 protein (Cdc42/Rac)-activated kinase 4,506,NVS_ENZ_hPAK4_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE10A,PDE10A,phosphodiesterase 10A,507,NVS_ENZ_hPDE10,loss,positive,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE10A,PDE10A,phosphodiesterase 10A,508,NVS_ENZ_hPDE10_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE1A,PDE1A,phosphodiesterase 1A,2277,NVS_ENZ_hPDE1A1,loss,positive,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE1A,PDE1A,phosphodiesterase 1A,2278,NVS_ENZ_hPDE1A1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the genePDE1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE1B,PDE1B,phosphodiesterase 1B,2279,NVS_ENZ_hPDE1B1,loss,positive,"Data from the assay component NVS_ENZ_hPDE1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1B1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE1B,PDE1B,phosphodiesterase 1B,2280,NVS_ENZ_hPDE1B1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE1A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the genePDE1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE2A,PDE2A,phosphodiesterase 2A,2281,NVS_ENZ_hPDE2A,loss,positive,"Data from the assay component NVS_ENZ_hPDE2A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE2A,PDE2A,phosphodiesterase 2A,2282,NVS_ENZ_hPDE2A_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE2A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE2A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE3A,PDE3A,phosphodiesterase 3A,2283,NVS_ENZ_hPDE3A,loss,positive,"Data from the assay component NVS_ENZ_hPDE3A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE3A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE3A,PDE3A,phosphodiesterase 3A,2284,NVS_ENZ_hPDE3A_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE3A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE3A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE4A,PDE4A,"phosphodiesterase 4A, cAMP-specific",509,NVS_ENZ_hPDE4A1,loss,positive,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE4A,PDE4A,"phosphodiesterase 4A, cAMP-specific",510,NVS_ENZ_hPDE4A1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE4B,PDE4B,phosphodiesterase 4B,2285,NVS_ENZ_hPDE4B1,loss,positive,"Data from the assay component NVS_ENZ_hPDE4B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4B1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE4B,PDE4B,phosphodiesterase 4B,2286,NVS_ENZ_hPDE4B1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPD4B1_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4B1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PD4B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE4C,PDE4C,phosphodiesterase 4C,2287,NVS_ENZ_hPDE4C1,loss,positive,"Data from the assay component NVS_ENZ_hPD4C1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4C1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE4C,PDE4C,phosphodiesterase 4C,2288,NVS_ENZ_hPDE4C1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE4C1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPD4C1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4C1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE4D,PDE4D,phosphodiesterase 4D,2289,NVS_ENZ_hPDE4D3,loss,positive,"Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4D3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE4D,PDE4D,phosphodiesterase 4D,2290,NVS_ENZ_hPDE4D3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE4D3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4D3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4D3.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE5A,PDE5A,"phosphodiesterase 5A, cGMP-specific",511,NVS_ENZ_hPDE5,loss,positive,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE5A,PDE5A,"phosphodiesterase 5A, cGMP-specific",512,NVS_ENZ_hPDE5_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE7A,PDE7A,phosphodiesterase 7A,2291,NVS_ENZ_hPDE7A,loss,positive,"Data from the assay component NVS_ENZ_hPDE7A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE7A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE7A,PDE7A,phosphodiesterase 7A,2292,NVS_ENZ_hPDE7A_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE10_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE7A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE7A.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE8A,PDE8A,phosphodiesterase 8A,2293,NVS_ENZ_hPDE8A1,loss,positive,"Data from the assay component NVS_ENZ_hPDE8A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE8A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE8A,PDE8A,phosphodiesterase 8A,2294,NVS_ENZ_hPDE8A1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE8A1_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE8A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE8A1.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PDE9A,PDE9A,phosphodiesterase 9A,2295,NVS_ENZ_hPDE9A2,loss,positive,"Data from the assay component NVS_ENZ_hPDE9A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE9A2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",inhibition
PDE9A,PDE9A,phosphodiesterase 9A,2296,NVS_ENZ_hPDE9A2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPDE9A2_Activator was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE9A2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE9A2.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PIK3CA,PIK3CA,"phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha",513,NVS_ENZ_hPI3Ka,loss,positive,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""phosphoinositol kinase"".",inhibition
PIK3CA,PIK3CA,"phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha",514,NVS_ENZ_hPI3Ka_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""phosphoinositol kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PRKACA,PRKACA,"protein kinase, cAMP-dependent, catalytic, alpha",515,NVS_ENZ_hPKA,loss,positive,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PRKACA,PRKACA,"protein kinase, cAMP-dependent, catalytic, alpha",516,NVS_ENZ_hPKA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PRKCZ,PRKCZ,"protein kinase C, zeta",517,NVS_ENZ_hPKCz,loss,positive,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PRKCZ,PRKCZ,"protein kinase C, zeta",518,NVS_ENZ_hPKCz_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PRKD2,PRKD2,protein kinase D2,519,NVS_ENZ_hPKD2,loss,positive,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
PRKD2,PRKD2,protein kinase D2,520,NVS_ENZ_hPKD2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PPM1A,PPM1A,"protein phosphatase, Mg2+/Mn2+ dependent, 1A",521,NVS_ENZ_hPPM1A,loss,positive,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",inhibition
PPM1A,PPM1A,"protein phosphatase, Mg2+/Mn2+ dependent, 1A",522,NVS_ENZ_hPPM1A_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PPP1CA,PPP1CA,"protein phosphatase 1, catalytic subunit, alpha isozyme",523,NVS_ENZ_hPPP1CA,loss,positive,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",inhibition
PPP1CA,PPP1CA,"protein phosphatase 1, catalytic subunit, alpha isozyme",524,NVS_ENZ_hPPP1CA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PPP2CA,PPP2CA,"protein phosphatase 2, catalytic subunit, alpha isozyme",525,NVS_ENZ_hPPP2CA,loss,positive,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",inhibition
PPP2CA,PPP2CA,"protein phosphatase 2, catalytic subunit, alpha isozyme",526,NVS_ENZ_hPPP2CA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PPP3CA,PPP3CA,protein phosphatase 3 catalytic subunit alpha,1744,NVS_ENZ_hPPP3CA,loss,positive,"Data from the assay component NVS_ENZ_hPPP3CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP3CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP3CA.
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""serine/threonine phosphatase"".",inhibition
PTEN,PTEN,phosphatase and tensin homolog,527,NVS_ENZ_hPTEN,loss,positive,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",inhibition
PTEN,PTEN,phosphatase and tensin homolog,528,NVS_ENZ_hPTEN_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN1,PTPN1,"protein tyrosine phosphatase, non-receptor type 1",529,NVS_ENZ_hPTPN1,loss,positive,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN1,PTPN1,"protein tyrosine phosphatase, non-receptor type 1",530,NVS_ENZ_hPTPN1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN11,PTPN11,"protein tyrosine phosphatase, non-receptor type 11",531,NVS_ENZ_hPTPN11,loss,positive,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN11,PTPN11,"protein tyrosine phosphatase, non-receptor type 11",532,NVS_ENZ_hPTPN11_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN12,PTPN12,"protein tyrosine phosphatase, non-receptor type 12",533,NVS_ENZ_hPTPN12,loss,positive,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN12,PTPN12,"protein tyrosine phosphatase, non-receptor type 12",534,NVS_ENZ_hPTPN12_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN13,PTPN13,"protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)",535,NVS_ENZ_hPTPN13,loss,positive,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN13,PTPN13,"protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)",536,NVS_ENZ_hPTPN13_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN14,PTPN14,"protein tyrosine phosphatase, non-receptor type 14",537,NVS_ENZ_hPTPN14,loss,positive,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN14,PTPN14,"protein tyrosine phosphatase, non-receptor type 14",538,NVS_ENZ_hPTPN14_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN2,PTPN2,"protein tyrosine phosphatase, non-receptor type 2",539,NVS_ENZ_hPTPN2,loss,positive,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN2,PTPN2,"protein tyrosine phosphatase, non-receptor type 2",540,NVS_ENZ_hPTPN2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN4,PTPN4,"protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)",541,NVS_ENZ_hPTPN4,loss,positive,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN4,PTPN4,"protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)",542,NVS_ENZ_hPTPN4_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN6,PTPN6,"protein tyrosine phosphatase, non-receptor type 6",543,NVS_ENZ_hPTPN6,loss,positive,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN6,PTPN6,"protein tyrosine phosphatase, non-receptor type 6",544,NVS_ENZ_hPTPN6_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPN9,PTPN9,"protein tyrosine phosphatase, non-receptor type 9",545,NVS_ENZ_hPTPN9,loss,positive,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"".",inhibition
PTPN9,PTPN9,"protein tyrosine phosphatase, non-receptor type 9",546,NVS_ENZ_hPTPN9_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPRB,PTPRB,"protein tyrosine phosphatase, receptor type, B",547,NVS_ENZ_hPTPRB,loss,positive,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",inhibition
PTPRB,PTPRB,"protein tyrosine phosphatase, receptor type, B",548,NVS_ENZ_hPTPRB_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPRC,PTPRC,"protein tyrosine phosphatase, receptor type, C",549,NVS_ENZ_hPTPRC,loss,positive,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",inhibition
PTPRC,PTPRC,"protein tyrosine phosphatase, receptor type, C",550,NVS_ENZ_hPTPRC_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPRF,PTPRF,"protein tyrosine phosphatase, receptor type, F",551,NVS_ENZ_hPTPRF,loss,positive,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",inhibition
PTPRF,PTPRF,"protein tyrosine phosphatase, receptor type, F",552,NVS_ENZ_hPTPRF_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTPRM,PTPRM,"protein tyrosine phosphatase, receptor type, M",553,NVS_ENZ_hPTPRM,loss,positive,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"".",inhibition
PTPRM,PTPRM,"protein tyrosine phosphatase, receptor type, M",554,NVS_ENZ_hPTPRM_Activator,gain,negative,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
RAF1,RAF1,"Raf-1 proto-oncogene, serine/threonine kinase",555,NVS_ENZ_hRAF1,loss,positive,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
RAF1,RAF1,"Raf-1 proto-oncogene, serine/threonine kinase",556,NVS_ENZ_hRAF1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ROCK1,ROCK1,"Rho-associated, coiled-coil containing protein kinase 1",557,NVS_ENZ_hROCK1,loss,positive,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
ROCK1,ROCK1,"Rho-associated, coiled-coil containing protein kinase 1",558,NVS_ENZ_hROCK1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SGK1,SGK1,serum/glucocorticoid regulated kinase 1,559,NVS_ENZ_hSGK1,loss,positive,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"".",inhibition
SGK1,SGK1,serum/glucocorticoid regulated kinase 1,560,NVS_ENZ_hSGK1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""serine/threonine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SIRT1,SIRT1,sirtuin 1,561,NVS_ENZ_hSIRT1,loss,positive,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",inhibition
SIRT1,SIRT1,sirtuin 1,562,NVS_ENZ_hSIRT1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SIRT2,SIRT2,sirtuin 2,563,NVS_ENZ_hSIRT2,loss,positive,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",inhibition
SIRT2,SIRT2,sirtuin 2,564,NVS_ENZ_hSIRT2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SIRT3,SIRT3,sirtuin 3,565,NVS_ENZ_hSIRT3,loss,positive,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"".",inhibition
SIRT3,SIRT3,sirtuin 3,566,NVS_ENZ_hSIRT3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""protein deacetylase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SRC,SRC,"SRC proto-oncogene, non-receptor tyrosine kinase",567,NVS_ENZ_hSRC,loss,positive,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
SRC,SRC,"SRC proto-oncogene, non-receptor tyrosine kinase",568,NVS_ENZ_hSRC_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
SYK,SYK,spleen tyrosine kinase,569,NVS_ENZ_hSyk,loss,positive,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
SYK,SYK,spleen tyrosine kinase,570,NVS_ENZ_hSyk_Activator,gain,negative,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
TEK,TEK,"TEK tyrosine kinase, endothelial",571,NVS_ENZ_hTie2,loss,positive,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
TEK,TEK,"TEK tyrosine kinase, endothelial",572,NVS_ENZ_hTie2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
NTRK1,NTRK1,"neurotrophic tyrosine kinase, receptor, type 1",573,NVS_ENZ_hTrkA,loss,positive,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
NTRK1,NTRK1,"neurotrophic tyrosine kinase, receptor, type 1",574,NVS_ENZ_hTrkA_Activator,gain,negative,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
FLT1,FLT1,fms-related tyrosine kinase 1,575,NVS_ENZ_hVEGFR1,loss,positive,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
FLT1,FLT1,fms-related tyrosine kinase 1,576,NVS_ENZ_hVEGFR1_Activator,gain,negative,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
KDR,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),577,NVS_ENZ_hVEGFR2,loss,positive,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
KDR,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),578,NVS_ENZ_hVEGFR2_Activator,gain,negative,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
FLT4,FLT4,fms-related tyrosine kinase 4,579,NVS_ENZ_hVEGFR3,loss,positive,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",inhibition
FLT4,FLT4,fms-related tyrosine kinase 4,580,NVS_ENZ_hVEGFR3_Activator,gain,negative,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ZAP70,ZAP70,zeta-chain (TCR) associated protein kinase 70kDa,581,NVS_ENZ_hZAP70,loss,positive,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"".",inhibition
ZAP70,ZAP70,zeta-chain (TCR) associated protein kinase 70kDa,582,NVS_ENZ_hZAP70_Activator,gain,negative,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""non-receptor tyrosine kinase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTGS1,PTGS1,prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase),583,NVS_ENZ_oCOX1,loss,positive,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",inhibition
PTGS1,PTGS1,prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase),584,NVS_ENZ_oCOX1_Activator,gain,negative,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
PTGS2,PTGS2,prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase),585,NVS_ENZ_oCOX2,loss,positive,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"".",inhibition
PTGS2,PTGS2,prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase),586,NVS_ENZ_oCOX2_Activator,gain,negative,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""cyclooxygenase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
MTHFR,MTHFR,methylenetetrahydrofolate reductase (NAD(P)H),587,NVS_ENZ_pMTHFR,loss,positive,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""methylenetetrahydrofolate reductase"".",inhibition
MTHFR,MTHFR,methylenetetrahydrofolate reductase (NAD(P)H),588,NVS_ENZ_pMTHFR_Activator,gain,negative,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""methylenetetrahydrofolate reductase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
CKB,CKB,"creatine kinase, brain",589,NVS_ENZ_rabI2C,loss,positive,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""imidazoline receptor"".",inhibition
CKB,CKB,"creatine kinase, brain",590,NVS_ENZ_rabI2C_Activator,gain,negative,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""imidazoline receptor"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Adcy5,Adcy5,adenylate cyclase 5,591,NVS_ENZ_rACFSKBinding,loss,positive,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""adenylyl cyclase"".",inhibition
Adcy5,Adcy5,adenylate cyclase 5,592,NVS_ENZ_rACFSKBinding_Activator,gain,negative,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""adenylyl cyclase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Ache,Ache,acetylcholinesterase,593,NVS_ENZ_rAChE,loss,positive,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"".",inhibition
Ache,Ache,acetylcholinesterase,594,NVS_ENZ_rAChE_Activator,gain,negative,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""acetylcholinesterase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Nos1,Nos1,"nitric oxide synthase 1, neuronal",595,NVS_ENZ_rCNOS,loss,positive,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"".",inhibition
Nos1,Nos1,"nitric oxide synthase 1, neuronal",596,NVS_ENZ_rCNOS_Activator,gain,negative,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Comt,Comt,catechol-O-methyltransferase,597,NVS_ENZ_rCOMT,loss,positive,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""methyltransferase"" intended target family, where the subfamily is ""o-methyltransferase"".",inhibition
Comt,Comt,catechol-O-methyltransferase,598,NVS_ENZ_rCOMT_Activator,gain,negative,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""methyltransferase"" intended target family, where the subfamily is ""o-methyltransferase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Maoa,Maoa,monoamine oxidase A,601,NVS_ENZ_rMAOAC,loss,positive,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",inhibition
Maoa,Maoa,monoamine oxidase A,602,NVS_ENZ_rMAOAC_Activator,gain,negative,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Maoa,Maoa,monoamine oxidase A,603,NVS_ENZ_rMAOAP,loss,positive,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",inhibition
Maoa,Maoa,monoamine oxidase A,604,NVS_ENZ_rMAOAP_Activator,gain,negative,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Maob,Maob,monoamine oxidase B,605,NVS_ENZ_rMAOBC,loss,positive,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",inhibition
Maob,Maob,monoamine oxidase B,606,NVS_ENZ_rMAOBC_Activator,gain,negative,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
Maob,Maob,monoamine oxidase B,607,NVS_ENZ_rMAOBP,loss,positive,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",inhibition
Maob,Maob,monoamine oxidase B,608,NVS_ENZ_rMAOBP_Activator,gain,negative,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",Activation
ADORA1,ADORA1,adenosine A1 receptor,609,NVS_GPCR_bAdoR_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
AGTR2,AGTR2,"angiotensin II receptor, type 2",610,NVS_GPCR_bAT2,loss,positive,"Data from the assay component NVS_GPCR_bAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
DRD1,DRD1,dopamine receptor D1,611,NVS_GPCR_bDR_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_bDR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bDR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HRH1,HRH1,histamine receptor H1,612,NVS_GPCR_bH1,loss,positive,"Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
NPY,NPY,neuropeptide Y,613,NVS_GPCR_bNPY_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_bNPY_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bNPY_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Htr4,Htr4,5 hydroxytryptamine (serotonin) receptor 4,614,NVS_GPCR_g5HT4,loss,positive,"Data from the assay component NVS_GPCR_g5HT4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_g5HT4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Nppa,Nppa,natriuretic peptide A,615,NVS_GPCR_gANPA,loss,positive,"Data from the assay component NVS_GPCR_gANPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gANPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nppa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""lyase"" intended target family, where the subfamily is ""guanylyl cyclase"".",Binding
Bdkrb2,Bdkrb2,"bradykinin receptor, beta 2",616,NVS_GPCR_gBK2,loss,positive,"Data from the assay component NVS_GPCR_gBK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gBK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Bdkrb2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Hrh2,Hrh2,histamine receptor H2,617,NVS_GPCR_gH2,loss,positive,"Data from the assay component NVS_GPCR_gH2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gH2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Ltb4r,Ltb4r,leukotriene B4 receptor,618,NVS_GPCR_gLTB4,loss,positive,"Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Cysltr1,Cysltr1,cysteinyl leukotriene receptor 1,619,NVS_GPCR_gLTD4,loss,positive,"Data from the assay component NVS_GPCR_gLTD4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTD4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cysltr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Chrm3,Chrm3,"cholinergic receptor, muscarinic 3, cardiac",620,NVS_GPCR_gMPeripheral_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_gMPeripheral_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gMPeripheral_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrm3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Oprk1,Oprk1,"opioid receptor, kappa 1",621,NVS_GPCR_gOpiateK,loss,positive,"Data from the assay component NVS_GPCR_gOpiateK was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gOpiateK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprk1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HTR2A,HTR2A,"5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled",622,NVS_GPCR_h5HT2A,loss,positive,"Data from the assay component NVS_GPCR_h5HT2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HTR5A,HTR5A,"5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled",623,NVS_GPCR_h5HT5A,loss,positive,"Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HTR6,HTR6,"5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled",624,NVS_GPCR_h5HT6,loss,positive,"Data from the assay component NVS_GPCR_h5HT6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HTR7,HTR7,"5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled",625,NVS_GPCR_h5HT7,loss,positive,"Data from the assay component NVS_GPCR_h5HT7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADORA1,ADORA1,adenosine A1 receptor,626,NVS_GPCR_hAdoRA1,loss,positive,"Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADORA2A,ADORA2A,adenosine A2a receptor,627,NVS_GPCR_hAdoRA2a,loss,positive,"Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADRA2A,ADRA2A,adrenoceptor alpha 2A,628,NVS_GPCR_hAdra2A,loss,positive,"Data from the assay component NVS_GPCR_hAdra2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADRA2C,ADRA2C,adrenoceptor alpha 2C,629,NVS_GPCR_hAdra2C,loss,positive,"Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADRB1,ADRB1,adrenoceptor beta 1,630,NVS_GPCR_hAdrb1,loss,positive,"Data from the assay component NVS_GPCR_hAdrb1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADRB2,ADRB2,"adrenoceptor beta 2, surface",631,NVS_GPCR_hAdrb2,loss,positive,"Data from the assay component NVS_GPCR_hAdrb2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
ADRB3,ADRB3,adrenoceptor beta 3,632,NVS_GPCR_hAdrb3,loss,positive,"Data from the assay component NVS_GPCR_hAdrb3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
AGTR1,AGTR1,"angiotensin II receptor, type 1",633,NVS_GPCR_hAT1,loss,positive,"Data from the assay component NVS_GPCR_hAT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
C5AR1,C5AR1,complement component 5a receptor 1,634,NVS_GPCR_hC5a,loss,positive,"Data from the assay component NVS_GPCR_hC5a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hC5a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene C5AR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
DRD1,DRD1,dopamine receptor D1,635,NVS_GPCR_hDRD1,loss,positive,"Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
DRD2,DRD2,dopamine receptor D2,636,NVS_GPCR_hDRD2s,loss,positive,"Data from the assay component NVS_GPCR_hDRD2s was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD2s, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
DRD4,DRD4,dopamine receptor D4,637,NVS_GPCR_hDRD4.4,loss,positive,"Data from the assay component NVS_GPCR_hDRD4.4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD4.4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
EDNRA,EDNRA,endothelin receptor type A,638,NVS_GPCR_hETA,loss,positive,"Data from the assay component NVS_GPCR_hETA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
EDNRB,EDNRB,endothelin receptor type B,639,NVS_GPCR_hETB,loss,positive,"Data from the assay component NVS_GPCR_hETB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HRH1,HRH1,histamine receptor H1,640,NVS_GPCR_hH1,loss,positive,"Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
LTB4R,LTB4R,leukotriene B4 receptor,641,NVS_GPCR_hLTB4_BLT1,loss,positive,"Data from the assay component NVS_GPCR_hLTB4_BLT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hLTB4_BLT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene LTB4R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
CHRM1,CHRM1,"cholinergic receptor, muscarinic 1",642,NVS_GPCR_hM1,loss,positive,"Data from the assay component NVS_GPCR_hM1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
CHRM2,CHRM2,"cholinergic receptor, muscarinic 2",643,NVS_GPCR_hM2,loss,positive,"Data from the assay component NVS_GPCR_hM2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
CHRM3,CHRM3,"cholinergic receptor, muscarinic 3",644,NVS_GPCR_hM3,loss,positive,"Data from the assay component NVS_GPCR_hM3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
CHRM4,CHRM4,"cholinergic receptor, muscarinic 4",645,NVS_GPCR_hM4,loss,positive,"Data from the assay component NVS_GPCR_hM4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
CHRM5,CHRM5,"cholinergic receptor, muscarinic 5",646,NVS_GPCR_hM5,loss,positive,"Data from the assay component NVS_GPCR_hM5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
TACR2,TACR2,tachykinin receptor 2,647,NVS_GPCR_hNK2,loss,positive,"Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
NPY1R,NPY1R,neuropeptide Y receptor Y1,648,NVS_GPCR_hNPY1,loss,positive,"Data from the assay component NVS_GPCR_hNPY1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
NPY2R,NPY2R,neuropeptide Y receptor Y2,649,NVS_GPCR_hNPY2,loss,positive,"Data from the assay component NVS_GPCR_hNPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
NTSR1,NTSR1,neurotensin receptor 1 (high affinity),650,NVS_GPCR_hNTS,loss,positive,"Data from the assay component NVS_GPCR_hNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NTSR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
OPRD1,OPRD1,"opioid receptor, delta 1",651,NVS_GPCR_hOpiate_D1,loss,positive,"Data from the assay component NVS_GPCR_hOpiate_D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_D1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
OPRM1,OPRM1,"opioid receptor, mu 1",652,NVS_GPCR_hOpiate_mu,loss,positive,"Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
OPRL1,OPRL1,opiate receptor-like 1,653,NVS_GPCR_hORL1,loss,positive,"Data from the assay component NVS_GPCR_hORL1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hORL1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
P2RY1,P2RY1,"purinergic receptor P2Y, G-protein coupled, 1",654,NVS_GPCR_hPY2,loss,positive,"Data from the assay component NVS_GPCR_hPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene P2RY1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
TBXA2R,TBXA2R,thromboxane A2 receptor,655,NVS_GPCR_hTXA2,loss,positive,"Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
AVPR1A,AVPR1A,arginine vasopressin receptor 1A,656,NVS_GPCR_hV1A,loss,positive,"Data from the assay component NVS_GPCR_hV1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hV1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AVPR1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Cckar,Cckar,cholecystokinin A receptor,657,NVS_GPCR_mCCKAPeripheral,loss,positive,"Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Cckbr,Cckbr,cholecystokinin B receptor,658,NVS_GPCR_mCKKBCentral,loss,positive,"Data from the assay component NVS_GPCR_mCKKBCentral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCKKBCentral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckbr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
HTR2C,HTR2C,"5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled",659,NVS_GPCR_p5HT2C,loss,positive,"Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Htr1a,Htr1a,"5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled",660,NVS_GPCR_r5HT_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_r5HT_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Htr1a,Htr1a,"5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled",661,NVS_GPCR_r5HT1_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_r5HT1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
PTAFR,PTAFR,platelet-activating factor receptor,662,NVS_GPCR_rabPAF,loss,positive,"Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adra1a,Adra1a,adrenoceptor alpha 1A,663,NVS_GPCR_rAdra1_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_rAdra1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adra1a,Adra1a,adrenoceptor alpha 1A,664,NVS_GPCR_rAdra1A,loss,positive,"Data from the assay component NVS_GPCR_rAdra1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adra1b,Adra1b,adrenoceptor alpha 1B,665,NVS_GPCR_rAdra1B,loss,positive,"Data from the assay component NVS_GPCR_rAdra1B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adra2a,Adra2a,adrenoceptor alpha 2A,666,NVS_GPCR_rAdra2_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_rAdra2_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra2_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adrb1,Adrb1,adrenoceptor beta 1,667,NVS_GPCR_rAdrb_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_rAdrb_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdrb_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adrb1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Crhr1,Crhr1,corticotropin releasing hormone receptor 1,668,NVS_GPCR_rCRF,loss,positive,"Data from the assay component NVS_GPCR_rCRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rCRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Crhr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""secretin receptor"".",Binding
Gabbr1,Gabbr1,gamma-aminobutyric acid (GABA) B receptor 1,669,NVS_GPCR_rGABBR,loss,positive,"Data from the assay component NVS_GPCR_rGABBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGABBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabbr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",Binding
Galr1,Galr1,galanin receptor 1,670,NVS_GPCR_rGalanin,loss,positive,"Data from the assay component NVS_GPCR_rGalanin was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGalanin, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Galr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Tspan17,Tspan17,tetraspanin 17,671,NVS_GPCR_rGHB,loss,positive,"Data from the assay component NVS_GPCR_rGHB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGHB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspan17. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",Binding
Hrh3,Hrh3,histamine receptor H3,672,NVS_GPCR_rH3,loss,positive,"Data from the assay component NVS_GPCR_rH3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rH3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Adra2b,Adra2b,adrenoceptor alpha 2B,673,NVS_GPCR_rmAdra2B,loss,positive,"Data from the assay component NVS_GPCR_rmAdra2B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmAdra2B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Grm1,Grm1,"glutamate receptor, metabotropic 1",674,NVS_GPCR_rmMGluR1,loss,positive,"Data from the assay component NVS_GPCR_rmMGluR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",Binding
Grm5,Grm5,"glutamate receptor, metabotropic 5",675,NVS_GPCR_rmMGluR5,loss,positive,"Data from the assay component NVS_GPCR_rmMGluR5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""metabotropic glutamate receptor"".",Binding
Tacr1,Tacr1,tachykinin receptor 1,676,NVS_GPCR_rNK1,loss,positive,"Data from the assay component NVS_GPCR_rNK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Tacr3,Tacr3,tachykinin receptor 3,677,NVS_GPCR_rNK3,loss,positive,"Data from the assay component NVS_GPCR_rNK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Ntsr1,Ntsr1,neurotensin receptor 1,678,NVS_GPCR_rNTS,loss,positive,"Data from the assay component NVS_GPCR_rNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ntsr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Oprm1,Oprm1,"opioid receptor, mu 1",679,NVS_GPCR_rOpiate_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_rOpiate_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Oprm1,Oprm1,"opioid receptor, mu 1",680,NVS_GPCR_rOpiate_NonSelectiveNa,loss,positive,"Data from the assay component NVS_GPCR_rOpiate_NonSelectiveNa was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelectiveNa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Oxtr,Oxtr,oxytocin receptor,681,NVS_GPCR_rOXT,loss,positive,"Data from the assay component NVS_GPCR_rOXT was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOXT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oxtr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Sstr1,Sstr1,somatostatin receptor 1,682,NVS_GPCR_rSST,loss,positive,"Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Trhr,Trhr,thyrotropin releasing hormone receptor,683,NVS_GPCR_rTRH,loss,positive,"Data from the assay component NVS_GPCR_rTRH was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rTRH, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Trhr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Avpr1a,Avpr1a,arginine vasopressin receptor 1A,684,NVS_GPCR_rV1,loss,positive,"Data from the assay component NVS_GPCR_rV1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rV1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Avpr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",Binding
Vipr1,Vipr1,vasoactive intestinal peptide receptor 1,685,NVS_GPCR_rVIP_NonSelective,loss,positive,"Data from the assay component NVS_GPCR_rVIP_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rVIP_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Vipr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""secretin receptor"".",Binding
KCNH2,KCNH2,"potassium voltage-gated channel, subfamily H (eag-related), member 2",686,NVS_IC_hKhERGCh,loss,positive,"Data from the assay component NVS_IC_hKhERGCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_hKhERGCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene KCNH2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",inhibition
Cacna1a,Cacna1a,"calcium channel, voltage-dependent, P/Q type, alpha 1A subunit",687,NVS_IC_rCaBTZCHL,loss,positive,"Data from the assay component NVS_IC_rCaBTZCHL was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaBTZCHL, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",inhibition
Cacna1b,Cacna1b,"calcium channel, voltage-dependent, N type, alpha 1B subunit",688,NVS_IC_rCaChN,loss,positive,"Data from the assay component NVS_IC_rCaChN was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaChN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",inhibition
Cacna1a,Cacna1a,"calcium channel, voltage-dependent, P/Q type, alpha 1A subunit",689,NVS_IC_rCaDHPRCh_L,loss,positive,"Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",inhibition
Grik1,Grik1,"glutamate receptor, ionotropic, kainate 1",690,NVS_IC_rKAR,loss,positive,"Data from the assay component NVS_IC_rKAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grik1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Kcnj1,Kcnj1,"potassium inwardly-rectifying channel, subfamily J, member 1",691,NVS_IC_rKATPCh,loss,positive,"Data from the assay component NVS_IC_rKATPCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKATPCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnj1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",inhibition
Kcnn1,Kcnn1,"potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1",692,NVS_IC_rKCaCh,loss,positive,"Data from the assay component NVS_IC_rKCaCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKCaCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnn1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""potassium channel"".",inhibition
Scn1a,Scn1a,"sodium channel, voltage-gated, type I, alpha subunit",693,NVS_IC_rNaCh_site2,loss,positive,"Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""sodium channel"".",inhibition
GABRA1,GABRA1,"gamma-aminobutyric acid (GABA) A receptor, alpha 1",694,NVS_LGIC_bGABAR_Agonist,loss,positive,"Data from the assay component NVS_LGIC_bGABAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
GABRA1,GABRA1,"gamma-aminobutyric acid (GABA) A receptor, alpha 1",695,NVS_LGIC_bGABARa1,loss,positive,"Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
GABRA5,GABRA5,"gamma-aminobutyric acid (GABA) A receptor, alpha 5",696,NVS_LGIC_bGABARa5,loss,positive,"Data from the assay component NVS_LGIC_bGABARa5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
HTR3A,HTR3A,"5-hydroxytryptamine (serotonin) receptor 3A, ionotropic",697,NVS_LGIC_h5HT3,loss,positive,"Data from the assay component NVS_LGIC_h5HT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_h5HT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
CHRNA2,CHRNA2,"cholinergic receptor, nicotinic, alpha 2 (neuronal)",698,NVS_LGIC_hNNR_NBungSens,loss,positive,"Data from the assay component NVS_LGIC_hNNR_NBungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_hNNR_NBungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRNA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Gria1,Gria1,"glutamate receptor, ionotropic, AMPA 1",699,NVS_LGIC_rAMPA,loss,positive,"Data from the assay component NVS_LGIC_rAMPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rAMPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gria1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Gabra1,Gabra1,"gamma-aminobutyric acid (GABA) A receptor, alpha 1",700,NVS_LGIC_rGABAR_NonSelective,loss,positive,"Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Gabra6,Gabra6,"gamma-aminobutyric acid (GABA) A receptor, alpha 6",701,NVS_LGIC_rGABARa6,loss,positive,"Data from the assay component NVS_LGIC_rGABARa6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABARa6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Grin1,Grin1,"glutamate receptor, ionotropic, N-methyl D-aspartate 1",702,NVS_LGIC_rGluNMDA_Agonist,loss,positive,"Data from the assay component NVS_LGIC_rGluNMDA_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Grin1,Grin1,"glutamate receptor, ionotropic, N-methyl D-aspartate 1",703,NVS_LGIC_rGluNMDA_MK801_Agonist,loss,positive,"Data from the assay component NVS_LGIC_rGluNMDA_MK801_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_MK801_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Glra1,Glra1,"glycine receptor, alpha 1",704,NVS_LGIC_rGlyRStrySens,loss,positive,"Data from the assay component NVS_LGIC_rGlyRStrySens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGlyRStrySens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Glra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
Chrna7,Chrna7,"cholinergic receptor, nicotinic, alpha 7 (neuronal)",705,NVS_LGIC_rNNR_BungSens,loss,positive,"Data from the assay component NVS_LGIC_rNNR_BungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rNNR_BungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrna7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",inhibition
TSPO,TSPO,translocator protein (18kDa),706,NVS_MP_hPBR,loss,positive,"Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",inhibition
Tspo,Tspo,translocator protein,707,NVS_MP_rPBR,loss,positive,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",inhibition
ESR1,ESR1,estrogen receptor 1,708,NVS_NR_bER,loss,positive,"Data from the assay component NVS_NR_bER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
PGR,PGR,progesterone receptor-like,709,NVS_NR_bPR,loss,positive,"Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
AR,AR,androgen receptor,710,NVS_NR_cAR,loss,positive,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
AR,AR,androgen receptor,711,NVS_NR_hAR,loss,positive,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",712,NVS_NR_hCAR_Agonist,loss,positive,"Data from the assay component NVS_NR_hCAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",713,NVS_NR_hCAR_Antagonist,loss,positive,"Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
ESR1,ESR1,estrogen receptor 1,714,NVS_NR_hER,loss,positive,"Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",715,NVS_NR_hFXR_Agonist,loss,positive,"Data from the assay component NVS_NR_hFXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",716,NVS_NR_hFXR_Antagonist,loss,positive,"Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",717,NVS_NR_hGR,loss,positive,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
PPARA,PPARA,peroxisome proliferator-activated receptor alpha,718,NVS_NR_hPPARa,loss,positive,"Data from the assay component NVS_NR_hPPARa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,719,NVS_NR_hPPARg,loss,positive,"Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
PGR,PGR,progesterone receptor,720,NVS_NR_hPR,loss,positive,"Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",721,NVS_NR_hPXR,loss,positive,"Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
RARA,RARA,"retinoic acid receptor, alpha",722,NVS_NR_hRAR_Antagonist,loss,positive,"Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
RARA,RARA,"retinoic acid receptor, alpha",723,NVS_NR_hRARa_Agonist,loss,positive,"Data from the assay component NVS_NR_hRARa_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRARa_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
THRA,THRA,"thyroid hormone receptor, alpha",724,NVS_NR_hTRa_Antagonist,loss,positive,"Data from the assay component NVS_NR_hTRa_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hTRa_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Binding
Esr1,Esr1,estrogen receptor 1 (alpha),725,NVS_NR_mERa,loss,positive,"Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
Ar,Ar,androgen receptor,726,NVS_NR_rAR,loss,positive,"Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
Nr3c2,Nr3c2,"nuclear receptor subfamily 3, group C, member 2",727,NVS_NR_rMR,loss,positive,"Data from the assay component NVS_NR_rMR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rMR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nr3c2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Binding
Sigmar1,Sigmar1,sigma non-opioid intracellular receptor 1,728,NVS_OR_gSIGMA_NonSelective,loss,positive,"Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",Binding
FKBP1A,FKBP1A,"FK506 binding protein 1A, 12kDa",729,NVS_OR_hFKBP12,loss,positive,"Data from the assay component NVS_OR_hFKBP12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_hFKBP12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene FKBP1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""chaperone"".",Binding
Slc6a3,Slc6a3,"solute carrier family 6 (neurotransmitter transporter, dopamine), member 3",730,NVS_TR_gDAT,loss,positive,"Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
SLC29A1,SLC29A1,"solute carrier family 29 (equilibrative nucleoside transporter), member 1",731,NVS_TR_hAdoT,loss,positive,"Data from the assay component NVS_TR_hAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC29A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""nucleoside transporter"".",Binding
SLC6A3,SLC6A3,"solute carrier family 6 (neurotransmitter transporter), member 3",732,NVS_TR_hDAT,loss,positive,"Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
SLC6A2,SLC6A2,"solute carrier family 6 (neurotransmitter transporter), member 2",733,NVS_TR_hNET,loss,positive,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
SLC6A4,SLC6A4,"solute carrier family 6 (neurotransmitter transporter), member 4",734,NVS_TR_hSERT,loss,positive,"Data from the assay component NVS_TR_hSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
Slc29a1,Slc29a1,"solute carrier family 29 (equilibrative nucleoside transporter), member 1",735,NVS_TR_rAdoT,loss,positive,"Data from the assay component NVS_TR_rAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc29a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""nucleoside transporter"".",Binding
Slc6a2,Slc6a2,"solute carrier family 6 (neurotransmitter transporter), member 2",736,NVS_TR_rNET,loss,positive,"Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
Slc6a4,Slc6a4,"solute carrier family 6 (neurotransmitter transporter), member 4",737,NVS_TR_rSERT,loss,positive,"Data from the assay component NVS_TR_rSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",Binding
Slc18a2,Slc18a2,"solute carrier family 18 (vesicular monoamine transporter), member 2",738,NVS_TR_rVMAT2,loss,positive,"Data from the assay component NVS_TR_rVMAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rVMAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc18a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""vesicular transporter"".",Binding
AR,AR,androgen receptor,739,OT_AR_ARELUC_AG_1440,gain,positive,"Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
AR,AR,androgen receptor,740,OT_AR_ARSRC1_0480,gain,positive,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
AR,AR,androgen receptor,741,OT_AR_ARSRC1_0960,gain,positive,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,742,OT_ER_ERaERa_0480,gain,positive,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,743,OT_ER_ERaERa_1440,gain,positive,"Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,744,OT_ER_ERaERb_0480,gain,positive,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),744,OT_ER_ERaERb_0480,gain,positive,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,745,OT_ER_ERaERb_1440,gain,positive,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),745,OT_ER_ERaERb_1440,gain,positive,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),746,OT_ER_ERbERb_0480,gain,positive,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),747,OT_ER_ERbERb_1440,gain,positive,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,750,OT_ERa_EREGFP_0120,gain,positive,"Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
ESR1,ESR1,estrogen receptor 1,751,OT_ERa_EREGFP_0480,gain,positive,"Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",753,OT_FXR_FXRSRC1_0480,gain,positive,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",754,OT_FXR_FXRSRC1_1440,gain,positive,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RXRA,RXRA,"retinoid X receptor, alpha",755,OT_NURR1_NURR1RXRa_0480,gain,positive,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
RXRA,RXRA,"retinoid X receptor, alpha",756,OT_NURR1_NURR1RXRa_1440,gain,positive,"Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,757,OT_PPARg_PPARgSRC1_0480,gain,positive,"Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,758,OT_PPARg_PPARgSRC1_1440,gain,positive,"Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".",Activation
AHR,AHR,aryl hydrocarbon receptor,806,TOX21_AhR_LUC_Agonist,gain,positive,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",Activation
FOS|JUN,FOS|JUN,FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene,1846,TOX21_AP1_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
JUN,JUN,jun proto-oncogene,1846,TOX21_AP1_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
AR,AR,androgen receptor,761,TOX21_AR_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
AR,AR,androgen receptor,762,TOX21_AR_BLA_Antagonist_ratio,loss,positive,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
AR,AR,androgen receptor,764,TOX21_AR_LUC_MDAKB2_Agonist,gain,positive,"Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
AR,AR,androgen receptor,1822,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide,gain,positive,"Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_Counterscreen was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_Counterscreen, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
AR,AR,androgen receptor,1816,TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,loss,positive,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
AR,AR,androgen receptor,765,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881,loss,positive,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_Specificity was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_Specificity, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
NFE2L2,NFE2L2,"nuclear factor, erythroid 2-like 2",1110,TOX21_ARE_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",Activation
CYP19A1,CYP19A1,"cytochrome P450, family 19, subfamily A, polypeptide 1",767,TOX21_Aromatase_Inhibition,loss,positive,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",inhibition
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",2047,TOX21_CAR_Agonist,gain,positive,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",Activation
NR1I3,NR1I3,"nuclear receptor subfamily 1, group I, member 3",2049,TOX21_CAR_Antagonist,loss,positive,"Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",2368,TOX21_CASP3_CHO,gain,positive,"The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity in the CHO cell line following compound treatment as an indicator of induction of apoptosis.",Activation
CASP3,CASP3,"caspase 3, apoptosis-related cysteine peptidase",2366,TOX21_CASP3_HEPG2,gain,positive,"The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity in the HepG2 cell line following compound treatment as an indicator of induction of apoptosis.",Activation
ATAD5,ATAD5,"ATPase family, AAA domain containing 5",781,TOX21_ELG1_LUC_Agonist,gain,positive,"Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.",Activation
ESR1,ESR1,estrogen receptor 1,785,TOX21_ERa_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
ESR1,ESR1,estrogen receptor 1,786,TOX21_ERa_BLA_Antagonist_ratio,loss,positive,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
ESR1,ESR1,estrogen receptor 1,788,TOX21_ERa_LUC_VM7_Agonist,gain,positive,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
ESR1,ESR1,estrogen receptor 1,2211,TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780,gain,NA,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
ESR1,ESR1,estrogen receptor 1,2053,TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2,loss,positive,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
ESR1,ESR1,estrogen receptor 1,789,TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,loss,positive,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_Specificity was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_Specificity, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
ESR2,ESR2,estrogen receptor 2 (ER beta),2115,TOX21_ERb_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
ESR2,ESR2,estrogen receptor 2 (ER beta),2119,TOX21_ERb_BLA_Antagonist_ratio,loss,positive,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
ESRRA,ESRRA,estrogen-related receptor alpha,2055,TOX21_ERR_Agonist,gain,positive,"Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",Activation
ESRRA,ESRRA,estrogen-related receptor alpha,2057,TOX21_ERR_Antagonist,loss,positive,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
ATF6,ATF6,activating transcription factor 6,1342,TOX21_ESRE_BLA_ratio,gain,positive,"Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",1119,TOX21_FXR_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_FXR_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
NR1H4,NR1H4,"nuclear receptor subfamily 1, group H, member 4",1120,TOX21_FXR_BLA_antagonist_ratio,gain,positive,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_FXR_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",793,TOX21_GR_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",Activation
NR3C1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",794,TOX21_GR_BLA_Antagonist_ratio,loss,positive,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",inhibition
H2AFX,H2AFX,"H2A histone family, member X",1843,TOX21_H2AX_HTRF_CHO_Agonist_ratio,gain,positive,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
HDAC1,HDAC1,histone deacetylase 1,2061,TOX21_HDAC_Inhibition,loss,positive,"Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",inhibition
HIF1A,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",2065,TOX21_HRE_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
HSF1,HSF1,heat shock transcription factor 1,1113,TOX21_HSE_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",Activation
NFKB1,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,1346,TOX21_NFkB_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_NFkB_BLA_agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_NFkB_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.",Activation
TP53,TP53,tumor protein p53,1116,TOX21_p53_BLA_p1_ratio,gain,positive,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",Activation
TP53,TP53,tumor protein p53,1317,TOX21_p53_BLA_p2_ratio,gain,positive,"Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",Activation
TP53,TP53,tumor protein p53,1321,TOX21_p53_BLA_p3_ratio,gain,positive,"Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",Activation
TP53,TP53,tumor protein p53,1325,TOX21_p53_BLA_p4_ratio,gain,positive,"Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",Activation
TP53,TP53,tumor protein p53,1329,TOX21_p53_BLA_p5_ratio,gain,positive,"Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",Activation
ESRRA,ESRRA,estrogen-related receptor alpha,2068,TOX21_PGC_ERR_Agonist,gain,positive,"Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",Activation
ESRRA,ESRRA,estrogen-related receptor alpha,2070,TOX21_PGC_ERR_Antagonist,loss,positive,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
PPARD,PPARD,peroxisome proliferator-activated receptor delta,1124,TOX21_PPARd_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_PPARd_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
PPARD,PPARD,peroxisome proliferator-activated receptor delta,1125,TOX21_PPARd_BLA_antagonist_ratio,gain,positive,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_PPARd_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,802,TOX21_PPARg_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
PPARG,PPARG,peroxisome proliferator-activated receptor gamma,1127,TOX21_PPARg_BLA_antagonist_ratio,gain,positive,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_PPARg_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
PGR,PGR,progesterone receptor,2123,TOX21_PR_BLA_Agonist_ratio,gain,positive,"To identify the compounds that activate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK 293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) and a human PR-ligand binding domain/GAL4 DNA binding domain fusion protein was used to screen Tox21 10K compound library.",Activation
PGR,PGR,progesterone receptor,2127,TOX21_PR_BLA_Antagonist_ratio,loss,positive,"To identify the compounds that inhibit PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) and a human PR-ligand binding domain/GAL4 DNA binding domain fusion protein was used to screen Tox21 10K compound library. The agonist used to activate the receptor for antagonist mode in screening was 1 nM promegestone.",inhibition
PGR,PGR,progesterone receptor,2218,TOX21_PR_BLA_Followup_Agonist_ratio,gain,positive,"To identify the compounds that activate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK 293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) was used to screen Tox21 10K compound library. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA.",Activation
PGR,PGR,progesterone receptor-like,2218,TOX21_PR_BLA_Followup_Agonist_ratio,gain,positive,"To identify the compounds that activate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK 293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) was used to screen Tox21 10K compound library. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA.",Activation
PGR,PGR,progesterone receptor,2219,TOX21_PR_BLA_Followup_Antagonist_ratio,loss,positive,"To identify the compounds that activate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK 293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) was used to screen Tox21 10K compound library. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA.",inhibition
PGR,PGR,progesterone receptor-like,2219,TOX21_PR_BLA_Followup_Antagonist_ratio,loss,positive,"To identify the compounds that activate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK 293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an Upstream Activator Sequence (UAS) was used to screen Tox21 10K compound library. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA.",inhibition
PGR,PGR,progesterone receptor,2222,TOX21_PR_LUC_Followup_Agonist,gain,positive,"To identify the compounds that activate PR signaling, a PR-luciferase cell line containing a luciferase reporter gene under the control of a progesterone response element was used. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA. The cytotoxicity of tested compounds against the PR-bla cell line was tested in parallel by measuring the cell viability in the TOX21_PR_LUC_Followup assay.",Activation
PGR,PGR,progesterone receptor-like,2222,TOX21_PR_LUC_Followup_Agonist,gain,positive,"To identify the compounds that activate PR signaling, a PR-luciferase cell line containing a luciferase reporter gene under the control of a progesterone response element was used. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA. The cytotoxicity of tested compounds against the PR-bla cell line was tested in parallel by measuring the cell viability in the TOX21_PR_LUC_Followup assay.",Activation
PGR,PGR,progesterone receptor,2223,TOX21_PR_LUC_Followup_Antagonist,loss,positive,"To identify the compounds that inhibit PR signaling, a PR-luciferase cell line containing a luciferase reporter gene under the control of a progesterone response element was used. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA. The cytotoxicity of tested compounds against the PR-bla cell line was tested in parallel by measuring the cell viability in the TOX21_PR_LUC_Followup assay.",inhibition
PGR,PGR,progesterone receptor-like,2223,TOX21_PR_LUC_Followup_Antagonist,loss,positive,"To identify the compounds that inhibit PR signaling, a PR-luciferase cell line containing a luciferase reporter gene under the control of a progesterone response element was used. Followup indicates that this assay was run as a confirmatory screen for a subset of chemicals screened in the primary qHTS screen, TOX21_PR_BLA. The cytotoxicity of tested compounds against the PR-bla cell line was tested in parallel by measuring the cell viability in the TOX21_PR_LUC_Followup assay.",inhibition
NR1I2,NR1I2,"nuclear receptor subfamily 1, group I, member 2",2363,TOX21_PXR_Agonist,gain,positive,"To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used.",Activation
RARA,RARA,"retinoic acid receptor, alpha",1659,TOX21_RAR_LUC_Agonist,gain,positive,"Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",Activation
RARA,RARA,"retinoic acid receptor, alpha",1839,TOX21_RAR_LUC_Antagonist,NA,positive,"Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
RORC,RORC,RAR-related orphan receptor C,1661,TOX21_RORg_LUC_CHO_Antagonist,gain,positive,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",inhibition
RXRA,RXRA,"retinoid X receptor, alpha",1820,TOX21_RXR_BLA_Agonist_ratio,gain,positive,"Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",Activation
GLI3,GLI3,GLI family zinc finger 3,2106,TOX21_SSH_3T3_GLI3_Agonist,gain,positive,"Data from the assay component TOX21_SSH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SSH_3T3_GLI3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
GLI3,GLI3,GLI family zinc finger 3,2108,TOX21_SSH_3T3_GLI3_Antagonist,loss,positive,"Data from the assay component TOX21_SSH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SSH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",inhibition
THRA,THRA,"thyroid hormone receptor, alpha",803,TOX21_TR_LUC_GH3_Agonist,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
Thrb,Thrb,thyroid hormone receptor beta,803,TOX21_TR_LUC_GH3_Agonist,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
THRB,THRB,"thyroid hormone receptor, beta",803,TOX21_TR_LUC_GH3_Agonist,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
THRB |THRA,THRB |THRA,"thyroid hormone receptor, alpha | thyroid hormone receptor, beta",803,TOX21_TR_LUC_GH3_Agonist,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",Activation
THRA,THRA,"thyroid hormone receptor, alpha",2226,TOX21_TR_LUC_GH3_Agonist_Followup,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",Activation
THRB,THRB,"thyroid hormone receptor, beta",2226,TOX21_TR_LUC_GH3_Agonist_Followup,gain,positive,"Data from the assay component TOX21_TR_LUC_GH3_Agonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Agonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",Activation
THRA,THRA,"thyroid hormone receptor, alpha",804,TOX21_TR_LUC_GH3_Antagonist,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
Thrb,Thrb,thyroid hormone receptor beta,804,TOX21_TR_LUC_GH3_Antagonist,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
THRB,THRB,"thyroid hormone receptor, beta",804,TOX21_TR_LUC_GH3_Antagonist,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
THRB |THRA,THRB |THRA,"thyroid hormone receptor, alpha | thyroid hormone receptor, beta",804,TOX21_TR_LUC_GH3_Antagonist,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",inhibition
THRA,THRA,"thyroid hormone receptor, alpha",2227,TOX21_TR_LUC_GH3_Antagonist_Followup,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",inhibition
THRB,THRB,"thyroid hormone receptor, beta",2227,TOX21_TR_LUC_GH3_Antagonist_Followup,loss,positive,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist_Followup was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist_Followup, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB in the GH3 cell line using a luciferase reporter. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. This assay endpoint is designated followup because it was a confirmatory screen following the primary qHTS assay.",inhibition
THRA,THRA,"thyroid hormone receptor, alpha",2253,TOX21_TR_RXR_BLA_Agonist_Followup_ratio,gain,positive,GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific; catalogno.K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.,Activation
THRB,THRB,"thyroid hormone receptor, beta",2253,TOX21_TR_RXR_BLA_Agonist_Followup_ratio,gain,positive,GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific; catalogno.K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.,Activation
THRA,THRA,"thyroid hormone receptor, alpha",2257,TOX21_TR_RXR_BLA_Antagonist_Followup_ratio,loss,positive,GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific; catalogno.K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.,inhibition
THRB,THRB,"thyroid hormone receptor, beta",2257,TOX21_TR_RXR_BLA_Antagonist_Followup_ratio,loss,positive,GeneBLAzer RXRa-UAS-bla HEK293T assay (RXRa-bla) (ThermoFisherScientific; catalogno.K1697) was run in qHTS 1536 well format as a secondary assay for specificity of response in the TOX21_TR_GH3_LUC_Agonist assay.,inhibition
THRA,THRA,"thyroid hormone receptor, alpha",2230,TOX21_TRA_COA_Agonist_Followup_ratio,gain,positive,"The LanthaScreen TR-FRET TRa coactivator assay kits were used to determine TR activity in a cell-free functional assay in a 1,536-well qHTS format for a subset of chemicals screened in the primary qHTS screening assay TOX21_TR_GH3_LUC_Agonist assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.",Activation
THRA,THRA,"thyroid hormone receptor, alpha",2233,TOX21_TRA_COA_Antagonist_Followup_ratio,loss,positive,"The LanthaScreen TR-FRET TRa coactivator assay kits were used to determine TR activity in a cell-free functional assay in a 1,536-well qHTS format for a subset of chemicals screened in the primary qHTS screening assay TOX21_TR_GH3_LUC_Agonist assay. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.",inhibition
THRB,THRB,"thyroid hormone receptor, beta",2236,TOX21_TRB_BLA_Agonist_Followup_ratio,gain,positive,"This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. Followup indicates this assay was used as a secondary assay for specificity for a subset of chemicals that were screened in the primary qHTS assay, TOX21_TR_LUC_GH3_Agonist.",Activation
THRB,THRB,"thyroid hormone receptor, beta",2240,TOX21_TRB_BLA_Antagonist_Followup_ratio,loss,positive,"This assay contained the ligand-binding domain (LBD) of the human TRb fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer UAS-bla HEK293Tcell line. The reporter gene, b-lactamase, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain.",inhibition
THRB,THRB,"thyroid hormone receptor, beta",2244,TOX21_TRB_COA_Agonist_Followup_ratio,gain,positive,"The LanthaScreen TR-FRET TRb coactivator assay kits were used to determine TR activity in a cell-free functional assay in a 1,536-well qHTS format for a subset of chemicals screened in the primary qHTS screening assay TOX21_TR_GH3_LUC_Agonist assay. A time-resolved fluorescence resonance energy transfe r(TR-FRET) signal was indicative of coactivator (SRC-2) recruitment.",Activation
THRB,THRB,"thyroid hormone receptor, beta",2247,TOX21_TRB_COA_Antagonist_Followup_ratio,loss,positive,"The LanthaScreen TR-FRET TRb coactivator assay kits were used to determine TR activity in a cell-free functional assay in a 1,536-well qHTS format for a subset of chemicals screened in the primary qHTS screening assay TOX21_TR_GH3_LUC_Agonist assay. A time-resolved fluorescence resonance energy transfe r(TR-FRET) signal was indicative of coactivator (SRC-2) recruitment. T3 was used as the agonist for the antagonist assays.",inhibition
TRHR,TRHR,thyrotropin releasing hormone receptor,2364,TOX21_TRHR_HEK293_Agonist,gain,positive,Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay.,Activation
TRHR,TRHR,thyrotropin releasing hormone receptor,2365,TOX21_TRHR_HEK293_Antagonist,loss,positive,Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay. Agonists correspond to increased intracellular calcium. Antagonists correspond to decreased intracellular calcium.,inhibition
TSHR,TSHR,thyroid stimulating hormone receptor,2040,TOX21_TSHR_Agonist_ratio,gain,positive,"Data from the assay component TOX21_TSHR_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
TSHR,TSHR,thyroid stimulating hormone receptor,2043,TOX21_TSHR_Antagonist_ratio,loss,positive,"Data from the assay component TOX21_TSHR_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",inhibition
TSHR,TSHR,thyroid stimulating hormone receptor,2046,TOX21_TSHR_wt_ratio,gain,positive,"Data from the assay component TOX21_TSHR_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_wt_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",Activation
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",1131,TOX21_VDR_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_VDR_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.",Activation
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",1131,TOX21_VDR_BLA_agonist_ratio,gain,positive,"Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_VDR_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.",Activation
CYP24A1,CYP24A1,"cytochrome P450, family 24, subfamily A, polypeptide 1",1132,TOX21_VDR_BLA_antagonist_ratio,gain,positive,"Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_VDR_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.",inhibition
VDR,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",1132,TOX21_VDR_BLA_antagonist_ratio,gain,positive,"Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, TOX21_VDR_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.",inhibition
